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ABSTRACT
Glycosylation is the process by which a glycan is enzymatically attached to a pro-
tein, and is one of the most common post-translational modifications in nature. One
class of glycans is the glycosaminoglycans (GAGs), which are long, linear polysac-
charides that are variably sulfated and make up the glycan portion of proteoglycans
(PGs). PGs are located on the cellular surface and in the extracellular matrix (ECM),
making them important molecules for cell signaling and ligand binding. The GAG sul-
fation sequence is a determining factor for the signaling capacity of binding complexes,
so accurate determination of the sequence is critical. Historically, GAG sequencing
using tandem mass spectrometry (MS2) has been a difficult, manual process; how-
ever, with the advent of faster computational techniques and higher-resolution MS2,
high-throughput GAG sequencing is within reach.
Two steps in the pipeline of biomolecule sequencing using MS2 are discovery and
interpretation of spectral peaks. The discovery step traditionally is performed using
methods that rely on the concept of averagine, or the average molecular building block
for the analyte in question. These methods were developed for protein sequencing, but
viii
perform considerably worse on GAG sequences, due to the non-uniform distribution
of sulfur atoms along the chain and the relatively high isotope abundance of 34S.
The interpretation step traditionally is performed manually, which takes time and
introduces potential user error. To combat these problems, I developed GAGfinder,
the first GAG-specific MS2 peak finding and annotation software. GAGfinder is
described in detail in Chapter 2.
Another step in MS2 sequencing is the determination of the sequence using the
found MS2 fragments. For a given GAG composition, there are many possible se-
quences, and peak finding algorithms such as GAGfinder return a list of the peaks
in the MS2 mass spectrum. The many-to-many relationship between sequences and
fragments can be represented using a bipartite network, and node-ranking techniques
can be employed to generate likelihood scores for possible sequences. I developed a
bipartite network-based sequencing tool, GAGrank, based on a bipartite network ex-
tension of Google’s PageRank algorithm for ranking websites. GAGrank is described
in detail in Chapter 3.
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1Chapter 1
Review of Bioinformatics
Techniques for Glycan Sequencing
Using Tandem Mass Spectrometry
1.1 Biological Background
The traditional central dogma of molecular biology states that DNA is transcribed
into RNA, which is then translated into protein. This offers a tidy, but incomplete,
picture of what happens at the molecular level in living systems. Research over the
past century or so has unearthed more intricate molecular machinery that affects
this process, including epigenetic modifications and post-translational modifications
(PTMs), among others. Epigenetic modifications include DNA methylation, where
a methyl group is added to cytosine bases in a DNA sequence, and histone modifi-
cations, where the histone protein is chemically altered via methylation, acetylation,
or other means. Both of these types of epigenetic modifications alter gene expression
by affecting the binding capability of transcriptional proteins. PTMs are chemical
modifications that change how proteins interact with other molecules. Varieties of
PTMs include phosphorylation, ubiquitination, and glycosylation, among many oth-
2ers. Glycosylation is the process of covalently binding a carbohydrate polysaccharide
– termed a glycan – to a protein sequence, and is the general focus of this dissertation.
Protein glycosylation is classified according to the type of linkage to the amino acid
side chains: O-linked glycans, N -linked glycans, and glycosaminoglycans (GAGs). O-
linked glycans bind to the oxygen atom in a serine (Ser) or threonine (Thr) amino acid
residue, and the presence of a proline (Pro) residue at either the -1 or +3 position of
the protein sequence promotes O-linked glycosylation. There are eight core structures
of mucin-type O-glycans, all of which are initiated with an N -acetylgalactosamine
(GalNAc) residue. However, for other O-glycans, there are no consensus sequences,
and there is considerable diversity in the number and type of structures in this class of
glycan. N -linked glycans bind to the nitrogen atom in the side chain of the asparagine
(Asn) residue of a protein’s sequon, which is Asn-X-Ser or Asn-X-Thr, where X is any
amino acid except Pro. All animal N -linked glycans contain a branched pentasac-
charide core that is comprised of two β1→4-linked N -acetylglucosamine (GlcNAc)
residues – known as chitobiose – and three mannose (Man) residues. N -linked glycan
biosynthesis proceeds after formation of this core, and results in one of three classes
of branched glycans, depending on when the process is halted. High Man N -linked
glycans consist exclusively of Man residues attached to the chitobiose core, complex
N -linked glycans proceed further through biosynthesis and replace the non-core Man
residues with other monosaccharide residues, and hybrid N -linked glycans have had
biosynthesis arrested during the process of converting from high Man to complex.
GAGs are the third class of glycans, and they are long, linear polysaccharides that
typically comprise the glycan portion of proteoglycans (PGs), although they also can
be found attached to the cellular membrane or free-floating in the extracellular matrix
(ECM). GAGs covalently bind to proteins at Ser residues via a linker polysaccharide,
which depends on the GAG class. There are three main classes of sulfated GAGs that
3Figure 1·1: Characteristic disaccharides including linkage in-
formation and sulfation location information for each sulfated
GAG class.
each have a characteristic repeating disaccharide unit consisting of a uronic acid or
galactose residue and a hexosamine residue, as shown in Figure 1·1. The disaccharide
units are distinguished by their compositions, linkages, and sulfation locations. For
each class of GAG, individual sequences vary by their degree of polymerization (dp),
amount and location of sulfation, and uronic acid epimerization.
41.1.1 Heparan Sulfate and Heparin
The heparan sulfate (HS) disaccharide unit has more possible sulfation positions
than any other GAG class, and thus more variability. The uronic acid, which is
either iduronic acid (IdoA) or glucuronic acid (GlcA), can be sulfated at the 2-O
position. The hexosamine, which is always glucosamine (GlcN), can be sulfated at
the 2-N, 3-O, and 6-O positions, and can be acetylated at the 2-N position. Rarely,
the 2-N position of the GlcN is neither sulfated nor acetylated, resulting in a free
amine. HS chains organize into domains of heavy sulfation, heavy non-sulfation,
and hybrid domains. The HS disaccharide unit linkage is [-4GlcA/IdoAβ1-4GlcNα1-
]. HS is closely related to heparin (Hep), which follows the disaccharide structure
shown in Figure 1·1, though with slight differences. Hep has a higher IdoA content,
has more 2-N sulfation of the GlcN residue, and is overall more sulfated than HS.
Furthermore, Hep is found in granulated hematopoeitic lineage cells. Mast cells are
used for industrial production of biopharmaceutical heparin. HS, by contrast, is
expressed on plasma membrane-bound proteins on most cell surfaces and in ECM
PGs.
PGs that carry covalently bound HS GAGs include transmembrane syndecans and
glypicans and ECM PGs such as perlecan and agrin. Syndecans are involved in growth
factor binding [1–5], ECM adhesion [6–8], cell-cell adhesion [7, 9–11], and tumor
suppression [12]. Glypicans are involved in developmental morphogenesis [13, 14] and
regulation of cell signaling [15, 16]. Perlecan is a vascular ECM PG that is involved
in endothelial barrier function [17, 18]. Agrin has several various roles in embryonic
development [19, 20].
51.1.2 Chondroitin Sulfate and Dermatan Sulfate
The disaccharide unit for chondroitin sulfate (CS) and the closely related dermatan
sulfate (DS) is slightly different from that of HS. Once again, the uronic acid can
be either IdoA or GlcA – CS contains only GlcA, while DS can contain either – and
can be sulfated at the 2-O position. The hexosamine, which is always galactosamine
(GalN), can be sulfated at the 4-O or 6-O positions. Unlike HS, the GalN in CS
and DS is always N -acetylated. The CS/DS disaccharide linkage is [-4GlcA/IdoAβ1-
3GalNAcβ1-]. Historically, DS was referred to as chondroitin sulfate B, but that
terminology has fallen out of favor.
CS and DS are the bound GAGs for a wide range of PGs. Decorin is a small cellular
PG that is associated with fibrillogenesis [21–24]. Biglycan is a small ECM PG that is
associated with bone mineralization [25]. Versican is a hyalectan PG that is found in
ECM molecular lattices in many connective tissues and thereby regulates avaibility
of growth factors to the cell surface [26–28]. Neurocan is a hyalectan found only
in neural tissue, dysregulation of the expression of which is associated with bipolar
disorder [29]. Aggrecan is the largest hyalectan that provides the swelling pressure for
viscoelastic connective tissues including cartilage, tendon, and intervertebral disk [30,
31]. Brevican is a central nervous system hyalectan that is found in perineuronal nets,
the dysregulaton of which is associated with neurodegenerative and neuropsychiatric
disorders [32–34]. CS, like HS, is a GAG bound to perlecan, which is described above.
1.1.3 Keratan Sulfate
The keratan sulfate (KS) disaccharide unit is essentially a sulfated lactosamine unit
found on N - or O-glycans. Because of this, some glycoproteins are considered part-
time PGs if they become sulfated on lactosamine residues in certain biological context.
Rather than a uronic acid residue, it has a galactose (Gal) residue, which can be
6sulfated at the 6-O position. The hexosamine residue is GlcN, and can be sulfated at
the 6-O position. Like CS/DS, the GlcN is always N -acetylated. The KS disaccharide
linkage is [-3Galβ1-4GlcNAcβ1-]. There are three classes of KS: keratan sulfate type
I (KSI), keratan sulfate type II (KSII), and keratan sulfate type III (KSIII). These
classes differ in how they link to protein structures. KSI is linked to a high mannose
N -glycan precursor oligosaccharide linker that is N -linked to an Asn residue. KSII
is linked to the GalNAc residue of a mucin core 2 linker that is itself O-linked to a
Ser or Thr residue. KSIII is linked to a mannose residue that is O-linked to a Ser
residue.
KS PGs include the small leucine-rich PG (SLRP) family members fibromodulin,
associated with collagen fiber assembly [35], and lumican, which is most closely asso-
ciated with corneal transparency and also has a role in epithelial cell migration and
tissue repair [36]. Dysregulation of another SLRP family member, keratocan, plays a
role in the rare congenital corneal disease cornea plana 2 [37, 38].
1.2 Tandem Mass Spectrometry
Tandem mass spectrometry (MS2) is an analytical chemistry technique by which
biomolecular structure can be determined. There are multiple stages to the process,
illustrated in Figure 1·2. For biomolecules, the analyte is ionized using a gentle
ionization technique such as electrospray ionization (ESI) or matrix-assisted laser
desorption/ionization (MALDI). For GAGs, ESI is most often used because it in-
troduces ions into the gas phase with minimal vibrational excitation. The resulting
ion(s), termed the precursor ion(s), are resolved according to mass-to-charge ratio
(m/z ) by a mass analyzer. In this thesis, I consider mass spectral data generated
using a Fourier transform ion cyclotron resonance (FTICR) mass analyzer whereby
an ion image current in the time domain is transformed into the frequency domain
7Figure 1·2: Illustration of the stages of tandem mass spec-
trometry, from injection to detection. Adapted from https:
//en.wikipedia.org/Tandem_mass_spectrometry.
and then converted into m/z. An ion corresponding to a GAG saccharide of interest
is then selected for dissociation. This thesis focuses on data generated using elec-
tron activated dissociation (ExD). The m/z values, ion charge, and isotope pattern
define the compositions of molecular fragments created during the MS2 dissociation
experiment.
Most modern vendor software for MS2 analysis comes with a built-in peak finding
algorithm, and there are numerous algorithms that have been developed for structure
determination for specific purposes. The typical steps for a MS2 experiment include
spectrum analysis and peak interpretation. Spectrum analysis involves both detecting
and annotating fragment peaks. Peak interpretation includes reverse engineering the
biomolecular structure based on the fragment peaks in the spectrum. Historically,
these steps would be done manually in a tedious and time-consuming manner. In the
proteomics domain, however, with the sequencing of the genomes of many organisms,
it is possible to use database searching to identify the peptides from which tandem
mass spectra were produced.
MS2 is a valuable tool in glycomics research. Often, changes in glycan structure
either cause or result from different biological processes, including disease progression.
8For instance, due to the role of many glycans in cellular signaling, glycan structure is
a key player in various cancers [39–44]. The ability to reconstruct glycan sequences
is a key benefit to using MS2 for glycan analysis. MS2 can also be used to estimate
glycan abundances, which allows for differential expression analysis. The ability to
test for changes to glycan structure and relative abundance among different datasets
allows for robust study of these mechanisms, and exhibits the utility of MS2 as a key
method for glycan research.
1.3 Computational Techniques for Branched
Glycan Sequencing
Traditional sequencing methods, such as those used for nucleic acid or protein se-
quencing, are inappropriate for branched glycans (i.e., O-glycans and N -glycans),
due to their branched nature and extra complexity arising from different linkage pos-
sibilities. Furthermore, glycan biosynthesis is not template-driven, so there is not
a glycan code that is analogous to the genetic code of codons being translated into
amino acids. Therefore, more nuanced methods are required for automated sequenc-
ing of glycans. There are numerous algorithms for branched glycan sequencing, which
fall into two categories based on the approach used: database-assisted methods and
de novo methods. This subsection will contain a review of some of the techniques
used in these methods for branched glycan sequencing. However, it is not meant to
be a complete enumeration of all existing methods for branched glycan sequencing;
rather, it is meant to highlight some of the approaches used for this problem.
1.3.1 Database-Assisted Sequencing for Branched Glycans
One category of branched glycan sequencing methods is database-assisted sequenc-
ing. Curated databases such as GlyTouCan [45, 46], UniCarbKB [47], GlycomeDB
9[48], BCSDB [49], and GlycoEpitope [50], among others, store glycan structures and
their associated biochemical information found in the literature. Most methods that
rely on a structure database utilize one of these, depending on the exact question
they seek to answer. For instance, BCSDB is solely concerned with bacterial car-
bohydrate structures, and GlycoEpitope stores information about the relationship
between antibodies and glycan antigens.
GlycoMod [51] was published in 2001 with the goal of determining glycan composi-
tions for either N -linked or O-linked glycans, given user-input constraints. GlycoMod
relies on a list of existing glycan compositions and masses to match masses observed
in a mass spectrum. GlycoMod also links to UniProt databases [52] for matching
peptide sequences. A downside for GlycoMod is that it only returns glycan composi-
tions without any linkage information. This is due to GlycoMod being developed for
MS1 data rather than MS2 data, which would provide fragmentations of the glycan.
GlycosidIQ [53] was a glycan sequencing software suite published in 2004 that
matched observed MS2 fragment masses to a set of masses corresponding to resulting
fragments of an in silico fragmentation of known glycan structures from a database.
GlycosidIQ made use of a commercial glycan structure database, GlycoSuiteDB [54],
that contained curated and annotated glycan structures. GlycosidIQ used two scor-
ing algorithms to rank possible structures, structure-independent segmentation and
structure-relative correspondence. GlycosidIQ is no longer maintained.
Also in 2004, Lohmann and von der Lieth published GlycoFragment and Gly-
coSearchMS [55], two tools developed for glycan sequencing. The two tools worked
in tandem: GlycoFragment generated potential fragments for a mass spectrum, while
GlycoSearchMS compared them to those found in a database of theoretically gen-
erated spectra, SweetDB [56]. Candidate structures were scored by how well the
theoretical and observed peaks overlapped given a particular error tolerance. Neither
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GlycoFragment nor GlycoSearchMS is still maintained.
GlyDB [57] was published in 2007 for glycopeptide glycan annotation and is based
on the SEQUEST peptide sequence database search. GlyDB was developed for low-
energy CID MS2 that produces abundant B- and Y-ion fragments. GlyDB also im-
plements a linear string representation for branched glycans, although it does not
distinguish between isomeric monosaccharides. GlyDB is no longer maintained.
GlycoPep Grader (GPG) [58] was a glycoproteomics software suite published in
2012 that used a target-decoy approach (TDA) for estimating false discovery rates
(FDRs) for potential glycopeptides given MS2 data. GPG evaluated both the pep-
tide and glycan portion of glycopeptides in its implementation for sequencing. The
structure database used is uploaded by the user or selected at runtime. GPG is no
longer maintained.
GlycoPep Detector (GPD) [59] was a software suite developed by the same group
as GPG that was published in 2013 and was designed exclusively for electron transfer
dissociation (ETD) MS2 spectra. They used a set of experimentally validated N -
linked glycan spectra to train their algorithm on expected fragmentation patterns,
and used this information to guide its sequencing scoring. Also similar to GPG,
GPD used a TDA for estimating FDRs for candidate structures. GPD is no longer
maintained.
GlycoMaster DB [60] was published in 2014 and is software for identifying in-
tact N -linked glycopeptides given high-throughput MS2 spectra. GlycoMaster DB
searches both peptide and glycan databases separately to find the best match for the
glycopeptide of interest. GlycoMaster DB expects higher-energy collisional dissocia-
tion (HCD) spectra for glycan fragmentation and ETD spectra for peptide sequences.
GlycoMaster DB uses GlycomeDB for searching glycan structures.
Mayampurath et al. published a computational method, GlycoFragwork [61], for
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identifying intact glycoproteins in 2014 that has separate scoring algorithms depend-
ing on the method of dissociation used. GlycoFragwork uses TDA for FDR estimation
among potential structures. GlycoFragwork performs better when multiple modes of
fragmentation are combined in an experiment, resulting in complementary data about
the structure.
Another method for identifying intact N-linked glycopeptides is pGlyco [62]. p-
Glyco was published in 2016 and uses complementary HCD-MS2 and collision induced
dissociation (CID)-MS2 data to sequence the glycan portion. A novel TDA using
a finite mixture model is used for FDR estimation for potential glycan sequences.
pGlyco also uses MS3 for peptide backbone sequencing.
1.3.2 De Novo Sequencing for Branched Glycans
Sequencing methods that do not rely on a pre-existing database or library generated
at run time are classified as de novo sequencing methods. These techniques rely on
knowledge about the types of structure being analyzed without comparing to known,
annotated structures. There are numerous different approaches to sequencing without
databases.
The web application saccharide topology analysis tool (STAT) [63] was published
in 2000 and considers all possible structures that match a given mass. Users select
the composition that they feel is most likely, and STAT generates possible structures
for that composition that match prior biosynthetic rules. STAT is limited in its scope
to a size of ten monosaccharides, due to the numerical explosion associated with
generating all possible structures.
StrOligo [64, 65] was published in 2002 and uses dynamic programming to build
glycan structures based on MS2 spectra. StrOligo builds a relationship tree that
represents linkages between monosaccharides and proposes structures that match the
tree. The proposed structures follow biosynthetic rules for the glycan class in ques-
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tion. For instance, for N -glycans, StrOligo knows that the base of the tree will be a
branched trimannosyl core. StrOligo is no longer maintained.
GLYCH [66] was published in 2005 and makes use of the cross-ring and double-
fragmentation cleavages generated in high-energy collisional dissociation methods.
Many database-assisted sequencing methods only considered glycosidic bond frag-
ments for determining the sequence, but this leaves out a wealth of information about
the structure. For branched glycans, cross-ring cleavage fragments can localize link-
age information. GLYCH uses neighboring fragment information to build its most
likely structure. GLYCH is no longer maintained.
In 2009, Peltoniemi et al. [67] published a branch-and-bound method for de novo
glycan sequencing for intact glycopeptides. Like some of the above database-assisted
intact glycopeptide methods, this method utilizes MS2 at different collision energies
to generate complementary information about the peptide sequence and the glycan
sequence. The branch-and-bound algorithm is used to explore the search space of
possible N -glycans without full enumeration, and candidate sequences are scored by
how likely they would be to generate the spectra in question. This method is no
longer maintained.
Bo¨cker et al. published an algorithm in 2011 [68] that is an exact algorithm for
quickly generating glycan tree structures that match spectra. They focus away from
N -glycans, but with the caveat that it works on N -glycans if biological knowledge
restricts the search space for potential structures. This method considers glycan
topologies as rooted tree structures, restricting possibilities using biosynthetic infor-
mation. The method also restricts the number of peaks to consider to a user-input
value. There is no extant web application that uses the algorithm.
Dong et al. published a method in 2015 for building a branched glycan ontology
using a novel directed acyclic graph (DAG) method for representing the glycan [69].
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While this distinction may seem minor, encoding structures this way allows for the
sequencing problem to be broken up into subgraph units, and the sequence is built
iteratively from the “bottom up.” This technique speeds up analysis over existing
methods, which can be slow, depending on the amount of solution space the algorithm
searches.
In 2016, Sun et al. published a heuristic algorithm for de novo glycan sequencing
[70] that gives greater weight to MS2 fragment peaks found in the higher end of the
m/z dimension. This allows for a sort of top down sequencing algorithm, though it
is not to be confused with top-down proteomics. Like most other de novo sequencing
methods, they built the possible sequences as tree structures.
Recently, Hong et al. published GlycoDeNovo [71], which uses an interpretation
graph to build a glycan topology representation. GlycoDeNovo’s key innovation is
its IonClassifier method, which distinguishes B- and C-ions from others via machine
learning on training data. GlycoDeNovo ranks candidate topologies by their cumu-
lative IonClassifier scores. In contrast to other algorithms, which run in exponential
time, GlycoDeNovo runs in polynomial time, providing a considerable runtime reduc-
tion.
1.4 Computational Techniques for
Glycosaminoglycan Sequencing
GAG structures are different from branched glycans, mostly due to their linear struc-
ture, repeating backbone disaccharide, and the importance of modifications. There-
fore, the methods used for sequencing GAGs will be different than those used for
branched glycans. This subsection will be a brief review of some of the methods
developed for GAG sequencing using MS2. Due to the relative paucity of GAG se-
quencing methods to date, compared to methods for branched glycan sequencing, this
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subsection will not be broken up into separate parts.
The first effort to sequence GAGs was the heparin/HS oligosaccharide sequencing
tool (HOST), published in 2005 [72]. HOST was a software application that made
use of HS disaccharide composition information and MS2 fragmentation information
for enzymatically digested heparin using Microsoft Excel. This allowed for broad se-
quencing to be performed (i.e., the number of modifications on each monosaccharide),
but not site-specific modification information.
In 2008, Tissot et al. published an extension [73] of GlycoWorkbench [74] for
semiautomatic interpretation of GAG MS2 data. This software includes a visual editor
for glycan structures, GlycanBuilder, that allows users to build candidate structures.
The software then performs in silico fragmentation of the candidate structures in
order to generate all possible fragments for each of them. Now, the user can compare
the spectra to the possible fragments for the candidate structures.
Spencer et al. published a method in 2010 for GAG structure prediction using
disaccharide composition information and selective lyase digestion [75]. The stated
goal for this method was HS domain prediction, and they employed a modular, three-
step algorithm toward this end. The first step, chainmaker, builds candidate HS
chains based on user inputs such as the length of the chain, disaccharide composition
information, and the order of lyase digestion. The second step, chainbreaker, digests
the potential chains in silico to see if the resulting disaccharide compositions match
with the experimental ones. The final step, chainsorter, organizes the candidate
structures into user-defined domains. While this method was an important step
toward automated HS sequencing, it did not utilize MS2 data, and only considered
disaccharide information.
In 2014, Hu et al. published the first de novo sequencing algorithm for HS MS2
data, HS-SEQ [76]. This approach takes as input a MS2 peak list and information
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about the HS backbone and returns positional modification probabilities for each
HS modification location. HS-SEQ uses a spectrum graph model to map the path
from one sequence terminus to the other using the found peaks. HS-SEQ assigns
a confidence value and a uniqueness value to fragments based on how they fit into
the existing structure, and builds the consensus sequence using higher confidence
fragments first. The main drawback of HS-SEQ is that it does not produce a complete
sequence, but rather a backbone with modification probabilities.
GAG-ID [77] was published in 2015 for high-throughput HS identification using
liquid chromatography-tandem mass spectrometry (LC-MS2). GAG-ID uses a multi-
variate hypergeometric distribution to place peaks in low-intensity, medium-intensity,
and high-intensity bins. GAG-ID then compares the MS2 spectra to in silico frag-
mentation of an exhaustive list of candidate structures to score their likelihood. A
drawback of GAG-ID is that it requires an extensive chemical workup, including per-
methylation of N -acetyl groups and replacing sulfate groups with deuterated acetate.
This reduces the problem of sulfate loss but introduces many more wet lab steps.
The authors of GAG-ID published a multivariate mixture model for estimating the
accuracy of GAG-ID’s identifications [78]. They used an expectation-maximization
algorithm to separate correct identifications from incorrect identifications, and con-
cluded that GAG-ID is accurately identifying HS structures in their data.
As of this writing, the most recent published method for GAG sequencing is a
genetic algorithm for moving through the space of possible structures [79]. Like most
genetic algorithms, this method consists of three steps: initialization, crossover, and
mutation. In the initialization step, two random GAG structures are generated for the
given composition. In the crossover step, the two sequences exchange a modification
that they do not have in common. In the mutation step, a modification is moved along
the chain to a non-modified position for each sequence. These steps are repeated until
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a stopping criterion is met, which is typically when there is little or no change in the
fitness parameter, which is based on how the fragments of the potential structure
compare to the experimental data.
1.5 Future Directions in Glycosaminoglycan
Sequencing
Great strides have been made in the realm of GAG structure determination over the
past twenty years, but a consensus has not been reached regarding the best approach.
Disagreements on how to handle sulfate loss, whether to adduct cations, and the exact
nature of the methods are some of the culprits. Furthermore, the field is narrow
in scope, meaning fewer groups focus on it than other fields such as proteomics,
genomics, or even N -linked and O-linked glycomics. That said, the current options
for GAG sequencing all have positive qualities, and all are useful for predicting GAG
sequences given MS2 data.
GAG sequencing method performance is directly related to its inputs, and the
most crucial of these is the MS2 data. Improvements in MS2 methods will only
improve GAG sequencing methods, and can do so in a number of ways. First of all,
while ExD fragmentation produces a large complement of fragments, it still does not
sufficiently define all positions of backbone modification. This is the cause for some
of the ambiguity found in the existing approaches to GAG sequence determination.
Were a complete fragmentation of the sequence possible, any of these methods would
be able to select the correct sequence every time. Second, MS2 resolution and noise
reduction are constantly improving. Most current methods are developed for high-
resolution data, and operate with a very small error window for peak matching.
Distinguishing the signal from the noise is imperative in many statistical methods,
and GAG sequencing is no different. Having a higher signal-to-noise ratio will result
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in more found fragments, which will in turn improve performance for sequencing
methods. Third, reducing or removing false peak identifications will help reduce
ambiguity in identifications. In any mass spectra, there are a number of peaks that
do not correspond to the structure being analyzed. This could be due to sample
contamination, co-isolation, or noise spikes. These peaks harm the methods’ ability
to identify the correct structure given the found fragments.
An overlooked aspect of GAG sequencing is the determination of C5 epimers on
uronic acid residues. One unfortunate aspect of MS2 as a sequencing technique is
that it does not distinguish these epimers, since it is based on mass. Several groups
have shown that there are fragment ions in MS2 spectra that are diagnostic for GlcA
or IdoA, including cross-ring cleavages near the uronic acid C5 [80–82]. However, this
information is hardly automated, and deals with specific ions for specific sequences, so
generalizing the results for other uronic acid sites is unlikely to work. There are other
techniques, however, that could make progress in this sub-area of GAG sequencing.
For instance, a decision tree could be employed based on curated GAG sequence MS2
data that predicts whether each uronic acid in a GAG sequence is GlcA or IdoA. This
would most likely find more diagnostic ions for general GAG conditions.
Finally, while numerous machine learning and statistical methods have been em-
ployed for this problem, there are still others that have not been tried. The realms of
bioinformatics, probabilistic modeling, and machine learning are vast and constantly
growing, meaning more and more techniques are available for GAG sequencing. Only
after a more exhaustive utilization of these techniques can consensus of the best
method be approached.
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Chapter 2
Software for Peak Finding and
Elemental Composition
Assignment for Glycosaminoglycan
Tandem Mass Spectra
2.1 Introduction
Glycosaminoglycans (GAGs) exist either as the glycan portion of proteoglycans (PGs)
or as extracellular matrix (ECM) polysaccharides. The three classes of sulfated GAGs,
heparan sulfate (HS), chondroitin sulfate (CS), and keratan sulfate (KS), are charac-
terized by their long, linear chain, a repeating disaccharide unit (specific to each GAG
class), and variable patterns of sulfation and acetylation. Due to their locations on
the cell surface and in the ECM, as well as their sequence variation, they interact with
many growth factors and growth factor receptors and therefore modulate cellular sig-
naling and signal transduction pathways [83, 84]. Furthermore, spatial and temporal
regulation of the structures of GAGs characterizes physiology and pathophysiology in
eukaryotes. For instance, cancer cells remodel HS chains in their microenvironments
to avoid immune system targeting and allow proliferation [85]. In the motor neuron-
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degenerative disease amyotrophic lateral sclerosis, KS sulfation has been shown to
correlate with disease progression [86]. Indeed, GAG expression is required for em-
bryonic development [87], and GAGs are required for the proper functioning of all
mammalian biological systems [83]. Clearly, assigning GAG sequences from tandem
mass spectral data is necessary to establish their roles in diverse disease mechanisms.
Tandem mass spectrometry (MS2) entails isolating a precursor ion in the first
stage, and dissociating it in subsequent stages. Manual interpretation of tandem mass
spectra is tedious, time-consuming, and subjective. The first step of interpretation
is to assign the m/z and charge states for product ions. Once this is done, neutral
masses and isotope compositions can be assigned. Once these assignments are made,
an algorithm can be used to identify the GAG sequence [76].
Wolff and colleagues first applied electron activated dissociation methods to GAG
oligosaccharides, using both electron detachment dissociation (EDD) [80] and nega-
tive electron transfer dissociation (NETD) [88]. More recently, Huang and colleagues
showed the effectiveness of electron activated dissociation for minimizing sulfate loss
during HS mass spectrometry experiments [89]. Resulting tandem mass spectra after
electron activated dissociation are extremely rich in that they contain a large number
of product ions with varying charge states and isotope patterns. In the proteomics
domain, several computational methods for automatic recognition of isotopic pat-
terns and assignment of charge states and neutral mass values have been developed,
including THRASH [90], Decon2LS [91], and MS-Deconv [92], among others. These
methods assume product ion isotopic distributions will match the pattern produced
by the molecule’s average building block, or averagine; however, performance for GAG
saccharide tandem mass spectra is inadequate, due to the variable levels of sulfation
along their chains and the relatively abundant 34S isotope. Figure 2·1 shows two
examples of the large difference in the expected isotopic distributions of non-sulfated
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Figure 2·1: Comparison of expected isotopic distributions
for oligosaccharides with varying sulfation. A. Expected iso-
topic distribution of non-sulfated N -acetylglucosamine (GlcNAc) com-
pared with 3,6-O-sulfated, N -sulfated glucosamine (GlcNS3S6S). B.
Expected isotopic distribution of a non-sulfated octasaccharide with
acetyl groups at all four N positions compared with a hexadecasulfated
octasaccharide with sulfate groups at every possible position. Notice
the higher intensity at the A+2 peak for each fully sulfated oligosac-
charide; for the octasaccharide, the A+2 peak has the highest intensity,
making monoisotopic peak detection more difficult. Intensity is rela-
tive to the total intensity for the whole isotopic distribution. Key for
octasaccharide: [ΔHexA, HexA, GlcN, Ac, SO3].
and fully sulfated GAG fragments. Plainly, there is no GAG averagine that would
accurately recover the correct monoisotopic peak for each fragment, and that leads
to incorrect and missing assignments. Averagine-based approaches also do not assign
elemental compositions for monoisotopic ions, a step necessary for interpretation of
GAG saccharide tandem mass spectra. We sought to solve these problems.
Previous work in GAG tandem mass spectra analysis and annotation has typically
been a step in a further sequencing project. For instance, Yu and colleagues recently
sequenced the dermatan sulfate (DS) chain of the pericellular PG decorin using a
genetic algorithm based on known sulfate modification information from disaccharide
analysis, but mentioned in-house data interpretation software in passing [93]. And two
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GAG sequencing efforts from Chiu and colleagues, GAG-ID [77] and a multivariate
mixture model to estimate identification accuracy [78] represent recent attempts at
automated GAG sequencing using a weighted hypergeometric distribution to match
spectra to potential sequences. However, these papers both describe a method that
only considers high intensity peaks, rather than full isotopic distributions, and their
method requires an intense experimental workup for chemical derivatization that
replaces sulfate groups with heavy isotope acetyl groups.
Averagine-based deisotoping and charge state deconvolution algorithms were de-
veloped to circumvent the combinatorial explosion of the number of possible protein
sequences as the length of the chain increases. Due to this expansion, brute force
methods searching all possible proteins and protein product ions are not feasible.
While the number of possible GAGs also increases exponentially as a function of
chain length, the rate of increase is much lower. Figure 2·2 shows the log10 of the
number of possible structures of unmodified proteins, HS GAG saccharides, CS GAG
saccharides, and KS GAG saccharides, as a function of the length of the chain. No-
tice how the slopes for each GAG class are much smaller than the slope for proteins,
and consider how many more protein structures are possible when post-translational
modifications are included. Given the reduced search space and the variable sulfa-
tion along GAG chains, we developed a brute force product ion search algorithm
using the Python programming language, GAGfinder, for MS2 of GAG saccharides
of a given composition. GAGfinder iterates through every possible fragment of a
GAG composition at multiple charge states and tests its theoretical isotopic dis-
tribution against the observed spectral pattern. GAGfinder is available for down-
load at http://www.bumc.bu.edu/msr/software. This paper describes the steps in
GAGfinder and its performance as a means to identify the GAG monoisotopic prod-
uct ions, charge states, and neutral mass values versus an averagine-based peak finding
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Figure 2·2: Workflow for GAGfinder. The steps in GAGfinder’s
algorithm.
algorithm.
2.2 Experimental Procedures
2.2.1 GAGfinder Overview
A flowchart of the steps GAGfinder can be viewed in Figure 2·3. The details of
each step are described below. The term “product ion” will be used to refer to ions
observed in tandem mass spectra. The term “fragment” will be used to refer to
theoretical GAG saccharide substructures in a database.
Inputs – There are a number of required and optional inputs for GAGfinder to
return accurate results. The spectrum data must be in the mzML file format [94];
the raw data can be converted using any format conversion tool, such as MSConvert
[95] or compassXport (Bruker Daltonics, Inc.). Other required inputs include the
GAG class, the precursor m/z, the precursor charge, and the output format for the
results. Either the top percentile or the top N results can be returned, but not
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Figure 2·3: Plot of log10 of the number of possible structures
given oligomer length. The number of unmodified protein sequences
of a given oligomer length grows at a much faster rate than those of HS,
CS, or KS. The slower combinatorial growth rate allows GAGfinder’s
brute force search to be feasible.
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both. Optional inputs include the reducing-end derivatization formula (if any), the
adducted metal and the number of adducts (if there is metal adduction), the NETD
cation reagent (if NETD), a user-specified internal precision for mapping fragments
to isotopic distributions, a Boolean value for whether noise has already been removed
from the spectrum, and the number of labile sulfate losses to consider. These inputs
are arguments for the GAGfinder command line program.
Step 1: Load mzML file and connect to GAG fragment database – The first step
of GAGfinder is connecting to GAGfragDB, the database developed in SQLite for
easy storing and retrieval of all possible fragments of a precursor composition up to
hexadecamer. There are 4,150 unique compositions, 65,664 fragments, and 17,156,928
precursor-fragment mappings in GAGfragDB. The composition with the most possible
fragments – (1, 7, 8, 4, 15) with a key of (ΔHexA, HexA, HexN, Ac, SO3) – has
21,299 child fragments associated with it in HS. GAGfragDB includes a controlled
vocabulary designed to give each fragment a unique text identifier that does not
assume anything about the structure of the precursor or the fragment. In other
words, a fragment that has one composition but could be a terminal fragment or
any number of internal fragments will have only one identifier. Figure B·1 shows the
relational schema for GAGfragDB. The connection to GAGfragDB is established by
the Python sqlite3 module. After connecting to GAGfragDB, GAGfinder loads the
mzML file into Python using the pymzML module [96]. The pymzML module has a
number of spectrum processing methods, including centroiding peaks, finding peaks
in the spectrum within a particular error tolerance, and a number of others.
Step 2: Normalize scan(s) and remove noise – Once the tandem mass spectral
data have been loaded into Python, GAGfinder normalizes and averages the scans of
the data file using the total ion current (TIC). GAGfinder first divides each scan in
the file by the summed TIC intensity and then calculates the average over all scans.
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This step prevents any of the scans from biasing the results over the rest of the scans,
and is performed using methods in the pymzML package. After normalizing the scans,
GAGfinder removes noise from the spectrum, if the spectrum has not already been
denoised by the user prior to runtime. GAGfinder uses an implementation of the
noise reduction algorithm MasSPIKE [97].
Step 3: Determine precursor composition – Given the precursor m/z and charge,
the neutral mass of the precursor can be calculated, and based on this and the GAG
class, the precursor composition can be determined. GAGfinder considers metal ad-
duction and reducing end derivatization information in order to calculate the neutral
mass matching the composition in GAGfragDB. GAGfinder selects the composition
with the neutral mass closest to the calculated precursor mass as the precursor com-
position.
Step 4: Determine reducing end and non-reducing end monosaccharides – In order
to reduce the search space as much as possible, GAGfinder attempts to determine
the monosaccharides at each precursor saccharide terminus. There are several cases
in which this is possible, and Figure 2·4 shows the decision tree for determining this.
First, if the non-reducing end is an unsaturated uronic acid (in the cases of CS and
HS saccharides generated by polysaccharide lyase enzyme digestion), GAGfinder first
assumes that the reducing end monosaccharide is a hexuronic acid if the precursor
contains an odd number of monosaccharides, and a hexosamine if the precursor con-
tains an even number of monosaccharides. If this is not the case, then GAGfinder
checks whether there is an unequal number of the parts of the repeating disaccharide
for the current GAG class. If the number is unequal, then whichever monosaccharide
there is more of will be on both the non-reducing and reducing end. If the number
is equal, then GAGfinder cannot assign the end fragments and must search through
the entire search space.
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Figure 2·4: Flowchart describing steps in determining termi-
nal sugars. In several cases, GAGfinder can determine the reduc-
ing and non-reducing end sugars based on biosynthetic rules. In cases
where the sugars cannot be distinguished from the composition, both
monosaccharides of the class of GAG are considered as the terminal
sugars. RE = reducing end; NRE = non-reducing end.
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Step 5: Retrieve and modify all theoretical fragments for the precursor – Next,
GAGfinder retrieves every possible fragment for the current precursor from GAGfrag-
DB. The possible fragments stored in GAGfragDB include glycosidic bond cleavages
and all cross-ring cleavages except for those involving cleavage of adjacent bonds.
Figure B·2 shows each cross-ring cleavage GAGfinder considers. GAGfragDB stores
the theoretical fragments as neutral masses without considering sulfate losses or any
other modification information, so GAGfinder must modify and search each fragment
in order to maximize spectrum coverage. For each fragment, the modifications in-
cluded are water loss (for glycosidic fragments only), hydrogen loss (up to 2), sulfate
loss (up to the amount designated by the user), and reducing end derivatization (if
any). This information is used to determine whether a given fragment corresponds
to the reducing terminus. Product ions that have the same chemical composition
are merged. For every combination of these modifications, the fragments are pushed
through the algorithm.
Step 6: Score each theoretical fragment – Once all of the theoretical fragments
have been retrieved and modified as need be, they are scored against the tandem
mass spectrum. GAGfinder considers charge states from -1 to that of the precursor
ion plus one for each fragment. The decision to use the charge state of the precursor
ion plus one for the upper bound rather than that of the precursor ion is due to
two main reasons. First, the number of product ions with the same charge state
as the precursor is a small percentage of all of the product ions, meaning including
this charge state in GAGfinder’s searching would find only a few more product ions
while introducing more false positives. Second, many of the product ions with the
same charge state as the precursor are actually derivatives of the precursor, meaning
they provide no additional structural information. A theoretical relative isotopic
distribution (TID) is calculated for each fragment using the BRAIN algorithm [98],
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which employs polynomial expansion and applies the Newton-Girard theorem and
Vie`te’s formulae to this end. Once the TID is calculated, GAGfinder searches the
tandem mass spectrum for product ion peaks at the m/z values of the TID within
either a user-specified error tolerance or the default error tolerance of 20 parts-per-
million (ppm), storing them as the experimental isotopic distribution (EID). The EID
is then divided by the sum of its intensities so that it is also a relative distribution.
GAGfinder employs a G-test of goodness-of-fit to determine how similar the EID is
to the TID. Equation 2.1 shows the expression for the G score, where i is the index
of each peak in the matched isotopic distributions. According to the G-test, the G
score follows a chi-squared distribution under the null hypothesis that the EID has
the same distribution as the TID, and so can be used to compute p-values. This way,
a lower G score yields a higher p-value and thus represents a better fit.
G = 2
∑
i
EID i ln
(
EID i
TID i
)
(2.1)
Step 7: Rank product ions by G score and return top hits – Once all theoretical
fragments have been scored for goodness-of-fit, they are ranked by increasing G score.
Depending on whether the user requested the top percentile or top N results, those
results are saved into an output file. The output file contains the fragment m/z,
charge, intensity, annotation(s), G score, and error in ppm.
2.2.2 Data Acquisition and Preprocessing
We chose ten synthetic GAG standards to demonstrate the effectiveness of GAGfinder
(Figure 2·5). These standards were chosen due to their range of modification distri-
bution and precursor charges. Compounds 1 and 10 were synthesized as described
[99]. Compound 2 was a generous gift from Prof. Jian Liu, University of North
Carolina, Chapel Hill. Compound 3 was purchased from New England Biolabs (An-
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Figure 2·5: Structures of the ten synthetic standards used
for testing purposes. #1 has charge state of 4- and dissociation
method of NETD. #2 has charge state of 8- and dissociation method
of NETD. #3 has charge state of 5- and dissociation method of NETD.
#4 has charge state of 4- and dissociation method of EDD. #5 has
charge state of 6- and dissociation method of EDD. #6 has charge
state of 4- and dissociation method of NETD. #7 has charge state of
4- and dissociation method of NETD. #8 has charge state of 3- and
dissociation method of EDD. #9 has charge state of 3- and dissociation
method of NETD. #10 has charge state of 4- and dissociation method
of EDD. These standards were selected randomly because of their range
of modifications, length, and different dissociation methods.
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dover, MA). Compound 5 was purchased as Arixtra pharmaceutical preparation and
desalted by size exclusion chromatography. Compounds 4, 6, 7, and 8 were ac-
quired through a publicly available set of HS standard saccharides funded by the
NIH and maintained by the Zaia laboratory (http://www.bumc.bu.edu/zaia/gag-
synthetic-saccharides-available/). Compound 9 was isolated from porcine intestinal
mucosa as described [100]. These were subjected to electron detachment dissocia-
tion (EDD) or negative electron transfer dissociation (NETD) using a Bruker solariX
12T FTMS instrument. For each saccharide, GAGfinder was run retrieving 100%
of tested fragments, allowed for two sulfate losses, and used the default error of 20
ppm when mapping fragments to isotopic distributions. For saccharides 1-5, noise
was not previously removed, so GAGfinder implemented MasSPIKE to remove noise.
For saccharides 6-10, noise was previously removed. While in principle GAGfinder
can handle all classes of GAGs, we show results for HS saccharides for the present
work. Details regarding the tandem mass spectrometric acquisition methods can be
found in Hu, et al. [76]. Raw data files were converted to mzML format for input
into GAGfinder by either MSConvertGUI version 3.0.5084 [92] or compassXport com-
mand line utility 3.0.13 (Bruker Daltonics, Inc.). The mass spectrometry glycomics
data have been deposited to the ProteomeXchange Consortium via the PRIDE [101]
partner repository with the dataset identifier PXD009101.
We first sought to demonstrate the ability of GAGfinder to identify product ion
isotope clusters and charge states. To do this, we generated a list of product ions using
a traditional averagine-based method (the SNAP peak finder in Bruker DataAnal-
ysis 4.2) versus that for GAGfinder. In order to retrieve every product ion SNAP
identified, we set the quality factor threshold at 0, the signal-to-noise ratio (S/N)
threshold at 1, the relative intensity threshold (base peak) at 0%, and the absolute
intensity threshold at 0. For each GAG saccharide tested, we set the maximum charge
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state to the absolute value of the precursor charge state minus one, so that SNAP
would behave comparatively to GAGfinder. We set the repetitive building block to
C6H11.375N1.125O9.5S1.5, as used in previous methods [102]. SNAP returned a matrix
with columns for m/z, charge, intensity, resolving power, and quality factor.
2.2.3 Method Comparison
In order to judge GAGfinder’s performance in assigning tandem mass spectral mono-
isotopic product ions and charge states, we employed two separate statistical methods.
Each method required unbiased expert manual selection of monoisotopic product ion
peaks to serve as the set of true positives. In both methods we had GAGfinder return
scores for 100% of the tested theoretical fragments in order to ensure maximum
spectral coverage. The first method compared the GAGfinder performance against
that of a random selection of monoisotopic product ions. The second compared
GAGfinder’s performance to that of an averagine-based peak finding algorithm.
The first method for judging GAGfinder’s performance was a permutation test
that gauged GAGfinder’s performance in selecting true positive product ion peaks
compared against random selection of product ion peaks. First, we calculated a
performance score (PerfScore) for the GAGfinder results using the equation
PerfScore =
∑
j
GjHit j (2.2)
where j is the index of the current product ion, Gj is the G score for fragment j, and
Hit j =

1, if product ion j is a ”real” hit
0, if product ion j is not a ”real” hit
(2.3)
Once we calculated the performance score for the GAGfinder results, we permuted the
Hit vector 10,000 times and recalculated the performance score for each permutation.
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Since G scores are smaller for better fits, a smaller performance score represents a
better performance. The performance scores of the 10,000 permutations represent a
background distribution for performance against which we compared the GAGfinder
performance score. We plotted GAGfinder’s performance score against the back-
ground distribution and recorded its rank among all of the permuted performance
scores.
The second method for testing GAGfinder’s performance was a binary classifier
evaluation that compared the GAGfinder performance versus that of an averagine
based algorithm, SNAP. Precision-recall (P-R) curves show how the classifier’s preci-
sion and recall change as the classifier’s threshold is changed, and the area under the
curve (AUC) represents the classifier’s performance. Precision is defined as
Precison =
TP
TP + FP
(2.4)
where TP stands for true positives and FP stands for false positives, and recall, also
known as sensitivity, is defined as
Recall =
TP
TP + FN
(2.5)
where TP stands for true positives and FN stands for false negatives. A perfect
classifier has a precision and a recall of 1, and therefore, the closer the P-R AUC is to
1, the better the classifier has performed. The complete results for GAGfinder were
generated by requesting 100% of the product ions tested.
For GAGfinder results, we generated the vector of precision and recall values by
ordering the results by G score in ascending order and calculating the precision and
recall of GAGfinder at each G score threshold. Similarly, for SNAP, we ordered the
results by quality factor in descending order and calculated its precision and recall at
each quality factor threshold. Because the number of true positive peaks is limited
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to those fragment masses extracted from GAGfragDB, GAGfinder identifies fewer
monoisotopic peaks and charge states than does an averagine-based algorithm. In
order to compare the effectiveness of the peaks assigned in common by both algo-
rithms, we removed peaks that were not searched by GAGfinder. These peaks were
likely due to fragmentation or chemistry that GAGfinder does not consider.
2.3 Results
2.3.1 GAGfinder Performance Compared to Random
Sampling
For each of the ten GAG saccharide tandem mass spectra tested, the GAGfinder
performance score significantly outperformed that of the permutations. Table 2.1
compares GAGfinder’s performance score versus the mean and standard deviation
of the 10,000 random permutations for each saccharide; the distribution plots for
each saccharide can be seen in Figure B·3. For every compound, the PerfScore for
GAGfinder was in the top ten lowest scores, and for seven of the compounds, the Perf-
Score for GAGfinder was lower than every permutation’s PerfScore. This indicated
that GAGfinder produced a better performance than a random selection. Further-
more, the GAGfinder PerfScore was at least three standard deviations lower than
the average of the permutations for every saccharide, signifying significant outperfor-
mance compared to a random selection of peaks. There was no correlation between
the PerfScores for GAGfinder and the means and standard deviations of the permu-
tations, the dissociation method, or the precursor charge state. This indicated a lack
of bias for the GAGfinder algorithm. We concluded based on these numbers that
GAGfinder significantly outperforms a random selection of peaks.
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Table 2.1: Performance scores for GAGfinder compared to the
mean and standard deviation of the 10,000 permutations for
each of the ten synthetic compounds. In each case, GAGfinder’s
PerfScore was lower than at least 99.9% of the permutations’, indicating
a better performance.
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2.3.2 GAGfinder Performance Compared to
Averagine-Based Peak Finding
Table 2.2 compares the P-R curve AUCs for each spectrum for GAGfinder versus
SNAP, including summary statistics. The P-R curves for each spectrum are shown in
Figure B·4. The average GAGfinder P-R AUC is higher than the average SNAP P-R
AUC, while the median GAGfinder P-R AUC is almost equal to the median SNAP
P-R AUC. For seven of the ten spectra, GAGfinder has a higher P-R AUC. Of these
seven, four were generated by NETD, while the other three were generated by EDD,
and there is no correlation between charge state and performance difference between
GAGfinder and SNAP, indicating a lack of bias in the performance of each. These
numbers show that GAGfinder identifies monoisotopic peaks and charge states with
similar accuracy as does the averagine-based SNAP algorithm. We note again that
GAGfinder assigns the elemental compositions for all identified monoisotopic peaks.
Table 2.2: Area under the curve (AUC) of precision-recall
(PR) curves for GAGfinder analysis results compared to those
from SNAP.
Compound
Precursor
z
Dissociation
Method
GAGfinder
AUC
SNAP
AUC
#1 4- NETD 0.681 0.765
#2 8- NETD 0.315 0.100
#3 5- NETD 0.612 0.229
#4 4- EDD 0.688 0.652
#5 6- EDD 0.611 0.536
#6 4- NETD 0.628 0.574
#7 4- NETD 0.635 0.735
#8 3- EDD 0.716 0.682
#9 3- NETD 0.792 0.619
#10 4- EDD 0.646 0.703
Mean 0.632 0.560
Std. Dev. 0.125 0.222
Mean 0.641 0.636
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2.3.3 Runtime Numbers for GAGfinder
GAGfinder tracks and reports the length of runtime for each analysis. The amount
of time required for GAGfinder to search each fragment varies based on a variety of
factors, but the two that affect runtime the most are the number of possible frag-
ments and whether or not the noise was removed prior to analysis. Table 2.3 shows
GAGfinder’s runtime for each saccharide, as well as the total number of fragments
for that composition and charge state combination and whether or not the data was
pre-processed. As can be seen, analyzing a spectrum without noise removed greatly
increases the runtime. This is not due to GAGfinder’s noise removal step taking an
inordinate amount of time, but rather due to the larger number of data points to
average across scans. For instance, samples 1-5 did not have noise removed prior
to analysis, leaving that step for GAGfinder, which slowed down runtime. However,
samples 6-10 did have noise removed prior to analysis, and their faster runtime shows
it.
Table 2.3: Runtime for GAGfinder analysis for each saccha-
ride.
Compound
Precursor
z
Dissociation
Method
Runtime
(s)
# of tested
fragments/# of
possible fragments
Noise
removed?
#1 4- NETD 124.450 122/4,089 No
#2 8- NETD 176.900 827/99,120 No
#3 5- NETD 139.566 177/12,256 No
#4 4- EDD 76.679 252/9,147 No
#5 6- EDD 71.833 172/6,870 No
#6 4- NETD 1.740 413/7,398 Yes
#7 4- NETD 1.885 391/8,373 Yes
#8 3- EDD 1.724 257/4,932 Yes
#9 3- NETD 1.653 160/2,524 Yes
#10 4- EDD 1.830 428/8,379 Yes
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2.4 Discussion
Here we have presented GAGfinder, the first GAG-specific isotopic distribution find-
ing software for high resolution tandem mass spectra. GAGfinder uses a targeted,
brute force approach to search observed product ions against a set of theoretical frag-
ments calculated based on the precursor ion exact mass, composition based on GAG
biosynthesis rules, and expected NETD and EDD tandem mass spectrometry dissoci-
ation patterns. The software is easy to use on any operating system and outperforms
traditional peak finding software that was designed for peptide fragments. For this
manuscript, GAGfinder was run as a command line utility on a MacBook Pro, and
all tandem mass spectrometric data are available on the PRIDE Proteomics IDEntifi-
cations archive. While the software is currently only available in command line form,
a web application and interface is currently under development and will be available
soon.
We tested GAGfinder on the EDD and NETD spectra of a diverse set of synthetic
GAGs and showed that it accurately and consistently returns valid fragments for the
precursor being tested. GAGfinder consistently scored true positive fragments better
than false fragments across all tested GAGs, and performed comparably to tradi-
tional peak finding methods. Unlike traditional peak finding methods, GAGfinder
assigns elemental compositions to the monoisotopic product ions that are essential
for assigning the saccharide structure. While we tested GAGfinder exclusively on
high resolution spectra in the negative ion mode, the software was designed in prin-
ciple to handle any resolution level in either the negative or positive ion mode. For
low resolution spectra, we hypothesize that the G scores for assigned monoisotopic
product ions will be worse than with high resolution data; however, this is due to the
whole distribution of G scores shifting, and we anticipate that the correct IDs will
still be found at or near the top of the ranked list of G scores.
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While GAGfinder succeeds at identifying product ions that fall within the set de-
fined in the GAGfragDB, it does not identify product ions that arise from undefined
dissociation processes. Such undefined processes include rare dissociation patterns,
a charge state equal to or higher in absolute value than that of the precursor, and
random instrument noise. In these cases, traditional methods will have a greater like-
lihood of identifying m/z values and charge states but will not identify the elemental
composition. Furthermore, these ions are not actually useful for GAG structure de-
termination, which is the ultimate goal of GAG sequencing. While it is possible to
add rare dissociation processes to the GAGfragDB, this would increase search space
size at the expense of algorithm run time.
An interesting case where GAGfinder outperforms the traditional peak finding
method SNAP arises when the fragment composition substantially differs from that
of the averagine used. As shown in Figure 2·1, selecting an appropriate averagine
that fits all GAG fragments is difficult due to the variable number of sulfur atoms in
the fragments. Compound #9 contains a heavily sulfated reducing end, with three
sulfate groups on one GlcNAc. While GAGfinder finds the Y1-S and Y1 ions for this
compound and scores them in the top ten, SNAP is unable to find them. Figure
B·5 shows the annotated spectra, using the top 20 (or so) most intense fragments for
each saccharide, and Figure B·6 shows the portion of the spectrum containing these
fragments. In both cases, there are other isotopic distributions interspersed, but none
of these precisely overlap with their peaks.
Wolff and colleagues first showed how metal cationization can help curb sulfate
loss in EDD [103], an approach that has gained popularity in the years since. While
our group typically avoids metal adduction during GAG analysis due to the negative
effects on the instrument and the extra work up, we nonetheless designed GAGfinder
to be able to handle samples that have been cationized. In GAGfinder, cationization
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adds to the search space, and therefore the runtime, without necessarily improving
peak finding performance, reduced sulfate loss aside. While metal cationization can
help remove the ambiguity of tandem mass spectra, allowing for easier GAG sequenc-
ing, its utility is seen mostly in that step of the sequencing pipeline. GAGfinder is
only looking for fragments and isotopic distributions of given compositions, regard-
less of whether there is metal cationization or not, and therefore, metal cationization
should not affect GAGfinder’s peak finding performance.
In conclusion, use of GAGfinder will allow researchers to swiftly and accurately
assign elemental compositions and product ion types to product ions in GAG saccha-
ride tandem mass spectra. While GAGfinder was tested exclusively on pure, synthetic
compounds, we are evaluating its ability to assign product ion m/z, charge state, and
elemental composition for biological samples. Finally, we demonstrate that the use of
a brute force method for peak finding balances search space size and overall analysis
time compared to traditional methods.
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Chapter 3
GAGrank: Software for
Glycosaminoglycan Sequence
Ranking Using a Bipartite Graph
Model
3.1 Introduction
The sulfated glycosaminoglycans (GAGs) are long, linear polysaccharides that can
be found as the glycan portion of proteoglycans (PGs) on cell surfaces and in ex-
tracellular matrices (ECMs). There are three classes of sulfated GAG, each with its
own distinct repeating disaccharide unit (Figure 1·1) and biology. Heparan sulfate
(HS) has been shown to participate in or affect blood coagulation [104], growth factor
signaling [105], angiogenesis [106], and cell proliferation and migration [107]. Chon-
droitin sulfate (CS) has been shown to participate in or affect brain development [108],
spinal cord injury and neuroregeneration [109], neural stem cell migration [110], and
osteoarthritis [111]. Keratan sulfate (KS) has been shown to participate in or affect
corneal hydration [112], infection and wound repair [113], and cell migration [114].
As a part of membrane PGs and the ECM, GAGs bind numerous growth factors and
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growth factor receptors and thereby mediate cell-cell, cell-matrix, and host-pathogen
interactions. As such, the ability to sequence GAGs quickly and accurately is an
important step in understanding how changes in GAG sequences impact biological
mechanisms.
Algorithms based on THRASH [90] for identification of monoisotopic peaks and
estimation of elemental compositions do not suffice for GAGs due to the fact that the
sulfur and oxygen contents vary significantly among fragment ions, thus precluding
use of a single averagine for elemental composition approximation. Our group recently
developed a GAG-specific algorithm performing both of these steps, GAGfinder (see
Chapter 2). GAGfinder provides a list of peaks and annotations from a MS2 experi-
ment for the sequencing pipeline.
In a typical MS2 experiment, spectra are pre-processed depending on the type of
mass analyzer used. For ion cyclotron resonance and Orbitrap analyzers, the signal is
transformed from the time domain to the m/z domain, thereby filtering background
noise. The resulting m/z domain spectra can be interpreted using mass spectrometry
software.
Electron activated dissociation (ExD) is a general term that refers to use of ion-
ion or ion-electron reactions to dissociate the analyte. For fragmentation of anionic
species, including GAGs, ExD includes electron detachment dissociation (EDD) [115],
where the analyte is fragmented by detaching an electron with an electron beam, and
negative electron transfer dissociation (NETD) [116], where the analyte is fragmented
by transferring an electron from the anionic species to a cationic reagent. Wolff and
colleagues first demonstrated the efficacy of ExD for dissociating GAG oligosaccha-
rides in various applications, using both EDD [80, 117, 118] and NETD [88]. Huang
and colleagues have also shown the utility of ExD for GAG oligosaccharides in terms of
reducing labile sulfate loss [89]. Clearly, ExD methods show promise as the analytical
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tool of choice in GAG sequencing.
There are numerous existing methods for computational GAG sequencing, which
are described in detail in Chapter 1.4. These methods have succeeded in making GAG
sequencing faster and easier, but they each have drawbacks. HOST [72], the GAG
update to Glycoworkbench [73], and the approach described by Spenceret al. [75] use
the results of disaccharide analysis to guide their algorithm, meaning that the methods
are inappropriate for top- or middle-down glycomics studies. HS-SEQ [76] shows
promise in locating site-specific sulfation for HS oligosaccharides, but requires prior
knowledge about the HS backbone and does not handle mixtures as would be seen in
an LC-MS2 experiment. Furthermore, it only considers HS oligosaccharides, and does
not work on CS or KS GAGs. GAG-ID [77] shows promise in ranking individual GAG
sequences mapping to a given GAG composition, but requires an extensive chemical
workup involving permethylation, desulfation, and pertrideuteroacetylation. Duan
and Amster’s genetic algorithm [79] shows great promise for reducing search space
and computation time, but is a non-deterministic algorithm and therefore cannot
guarantee to reach a global optimum. We sought to develop a novel, deterministic
GAG sequencing method that has fewer steps before use than existing methods but
still delivers optimal performance.
At the core of any sequencing method using MS2 data is the relationship between
the unknown sequence and its fragments: the actual sequence is ascertained based on
the fragment ions generated in the fragmentation process. For GAGs, there are often
many possible sequences for a given composition, and in an ExD experiment, there is
a rich complement of product ions in the spectrum. The relationship between possible
sequences and observed product ions is many-to-many, and can be represented in a
network structure. In particular, the network structure is that of a bipartite network,
which is a network whose nodes can be separated into two distinct partitions with
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Figure 3·1: Example bipartite network of sequences and frag-
ments. This is a toy visualization of a bipartite network of sequences
and fragments. In this case, there are five sequences and six fragments.
An edge between a sequence and a fragment denotes that fragment be-
ing a possible fragment for that sequence. The edge width denotes the
type of fragment for that sequence; a wider edge represents a terminal
fragment, while a narrower edge represents an internal fragment.
edges only connecting nodes in one partition to nodes with the other partition. Fig-
ure 3·1 shows a graphical representation of the bipartite network relationship between
potential sequences and product ions.
The determination of node importance has been a topic of significant interest in
network analysis, in particular for social networks [119], protein-protein interaction
networks [120], and the World Wide Web [121], among many others. The concept
of centrality in network analysis aims to solve this problem, and there are numerous
existing algorithms for computing centrality measures. One such method is Page-
Rank [122], developed by Brin and Page in 1996 for Google as a way to rank web-
pages according to their importance for search engine optimization purposes. Briefly,
PageRank gives webpages higher importance values if they are linked to by other
important webpages. PageRank was developed for general networks (i.e. not bi-
partite networks), but a recent method, BiRank [123], was developed that adapts
the PageRank algorithm for the specific case of bipartite networks. The algorithm
pseudocode for BiRank is shown in Algorithm 3.1. Briefly, BiRank gives nodes in
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partition A higher importance if they are linked to important nodes in partition B,
and vice versa. Because of its design for bipartite networks, we employed BiRank
with the goal of determining precursor sequence based on fragmentation patterns in
the first GAG sequencing method developed using a network structure and network
analysis algorithm, GAGrank. GAGrank was developed as a command line inter-
face in the Python language. This paper describes the method, and demonstrates its
performance on a set of GAG standards.
Algorithm 3.1: BiRank Algorithm, adapted from [123]
Input: Weight matrix W , query vectors p0, q0, and hyper-parameters α, β;
Output: Ranking vectors p and u;
1 Symmetrically normalize W : S = D
− 1
2
u WD
− 1
2
p ;
2 Randomly initialize p and u;
3 while Stopping criteria is not met do
4 pi ← αSTui−1 + (1− α)p0;
5 ui ← βSpi−1 + (1− β)u0;
6 i← i+ 1;
7 return p and u
3.2 Experimental Procedures
3.2.1 GAGrank Overview
Figure 3·2 shows the steps in the GAGrank algorithm, the details of which are pre-
sented in the next several subsections.
Inputs – GAGrank has several inputs, both required and optional. The required
inputs are the peak/fragment list, the GAG class, the precursor ion m/z, and the
precursor ion charge, assuming unadducted deprotonated ions. The peak/fragment
list must be an output data file from our previous work, GAGfinder (see Chapter 2),
and the GAG class being analyzed must be denoted by its initials (i.e. HS, CS, or
KS). The optional inputs are the reducing end tag and the number of sulfate losses to
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Figure 3·2: Workflow for GAGrank algorithm. The steps in
GAGrank’s algorithm.
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consider. If the analyte was tagged on the reducing end to break potential molecular
symmetry, the user must denote what elements the tag adds to the sequence. For
instance, if the reducing end tag is 4-nitrophenol (PNP), the tag should be encoded as
C6H3NO2 rather than the PNP elemental composition of C6H5NO3, since that is the
number of each element that is added to the structure. For deciding an appropriate
number of sulfate losses for GAGrank to use, we recommend using the floor of two
times the free proton index (FPI) described in [124]. However, this input is up to the
user’s discretion.
Step 1: Load peak/fragment list – First, GAGrank loads the peak/fragment list
returned by GAGfinder into Python as a NumPy array with two columns, fragment
and G score. The G score is GAGfinder’s goodness-of-fit score for fitting experimental
isotopic distributions found in spectra to theoretical isotopic distributions. A smaller
G score represents a better fit between the two distributions.
Step 2: Determine precursor composition – Next, GAGrank utilizes the database
GAGfragDB to determine the precursor composition in a manner similar to GAG-
finder. GAGfragDB was developed in SQLite to store every possible fragment for a
given precursor composition, but it also stores useful information about precursors,
such as their chemical formula and monoisotopic mass. GAGrank selects the precursor
composition by comparing the neutral mass of the spectral precursor ion to the list
of neutral masses in GAGfragDB and picking the one that is arithmetically closest.
Step 3: Determine reducing end and non-reducing end monosaccharides – The
next step in GAGrank’s pipeline is also similar to one found in GAGfinder. By evalu-
ating the number and type of monosaccharides present in the precursor’s composition,
we can potentially determine the order of the monosaccharides in the oligosaccharide
backbone. For a detailed description of this process, see Chapter 2.
Step 4: Set up GAG backbone(s) – We can build the backbone(s) of the GAG
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sequence using our understanding of GAG sequence construction and the terminal
sugar residues determined in step 3. In the event that we cannot determine the
terminal sugar residues, we must consider two backbones; one with amino sugars
in the odd positions in the backbone, and another with amino sugars in the even
positions in the backbone. Given the backbone(s) of sugar residues and the GAG class
for the structure, we can define the positions for potential modifications (Figure 1·1).
Step 5: Generate all possible GAG sequences – We now have the backbone(s) of
the GAG, the potential modification positions along the backbone(s), and the number
of each modification (sulfation and acetylation). We use combinatorics to generate
each possible sequence for a given composition.
Step 6: Build bipartite network – Using Python’s NetworkX module [125], we
encode the relationships between each potential sequence and each fragment found
by GAGfinder in a bipartite network. For each potential sequence, we derive its
potential fragments by generating all terminal glycosidic fragments, terminal cross-
ring fragments, and internal glycosidic-glycosidic fragments. We do not consider
internal glycosidic-cross-ring or internal cross-ring-cross-ring fragments because they
are rare and of low-abundance, and do not add much additional information about
the sequence. We then compare this list of potential fragments to the those found
in the spectrum loaded in step 1, and place edges between the sequence and each
fragment in the intersection. Equation 3.1 shows how we encode the edge width for
these edges. The values for Equation 3.1 are based on those used in our previous
work, HS-SEQ [76]. In cases where a fragment could be both a terminal fragment
and an internal glycosidic-glycosidic fragment, the edge width is selected as a terminal
fragment. The tuning parameter r1 controls the effect that double glycosidic bond
fragments has on the performance of BiRank.
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wxy =

1.0, if fragment x is a terminal fragment in sequence y
0.2r1 , if fragment x is a double glycosidic fragment in sequence y
(3.1)
Step 7: Run BiRank and Return Results – The final step in GAGrank’s pipeline
is to run the BiRank algorithm [123] on the network built in step 6. The inputs for
BiRank include the graph’s weight matrix W , query vectors p0 and u0, and hyper-
parameters α and β. The weight matrix is symmetric, consisting of the edge weights
between nodes in the graph, as described in Equation 3.1. For nodes with no edge
between them, the weight wxy is given as 0. The query vectors store a prior belief
about the ranking criterion for the sequences and fragments before iterating through
the BiRank algorithm. For our purposes, we consider p to be the fragments vector
and u to be the sequences vector. The fragments’ query vector values are calculated
using equation 3.2:
p0x =
Ix
Gr2x
(3.2)
For fragment x, we assign the query value as its intensity divided by its GAGfinder
G score. The tuning parameter r2 controls the effect the G score has on the overall
score. The sequences’ query vector values are calculated using Equation 3.3:
u0y = (
∏
m
scorem)
r3 (3.3)
For sequence y, we assign the query value as the product of the residue likelihood
scores for each monosaccharide residue in the sequence. The residue likelihood is
calculated using Equation 3.4:
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scorem = 1.0− 0.6Nm − 0.3Sm
Nm =

1, if amine is unoccupied
0, otherwise
Sm =

1, if 3-O-sulfation without 6-O-sulfation
0, otherwise
(3.4)
Each residue has a maximum likelihood value of 1.0. If the residue is an amino
sugar that has a free amine group, the value is decreased by 0.6. If the residue is an HS
GlcN residue that is 3-O-sulfated and not also 6-O-sulfated, the value is decreased by
0.3. These deductions account for the rarity of free amines and 3-O-sulfation without
6-O-sulfation in nature. The tuning parameter r3 controls how much a sequence with
rare modification patterns is punished prior to running the BiRank algorithm. The
hyper-parameters α and β control how much of each iteration’s ranking score is due
to the query vectors for the fragments and sequences, respectively. A larger value for
either hyper-parameter weights the iterating results of BiRank more than the query
vector. Once the BiRank algorithm iterates to convergence, GAGrank outputs the
ranking of sequences with their ranking score into a tab-delimited file. A larger score
represents a higher ranking.
3.2.2 Data Acquisition and Preprocessing
We selected thirteen pure synthetic GAG standards on which to train and vali-
date GAGrank and two isomeric mixtures of pure synthetic GAG standards to show
GAGrank’s performance on mixtures, shown in Figure 3·3. These samples were se-
lected for their varying lengths, modification amounts and patterns, disaccharide
order, and precursor charge. Ten pure synthetic standards were selected as train-
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ing data and three pure standards were selected as validation data. Training com-
pounds 1, 3, 5, 8, 9, and 10 were acquired through a publicly available set of HS
standard saccharides funded by the NIH and maintained by the Zaia laboratory
(http://www.bumc.bu.edu/zaia/gag-synthetic-saccharides-available/). The remain-
ing training compounds, all of the validation compounds, and the compounds mixed
in the isomeric mixtures were synthesized as described [99, 126–128]. Each of the two
mixtures was tested in ratios of 100:0, 90:10, 70:30, 50:50, 30:70, 10:90, and 0:100.
Each sample was subjected to either electron detachment dissociation (EDD) or
negative electron transfer dissociation (NETD) using a Bruker SolariX 12T FTMS
instrument. The spectra were converted to centroided mzML using the compass-
Xport command line utility 3.0.13 (Bruker Daltonics, Inc.). Elemental compositions
of tandem mass spectral peaks corresponding to GAG fragments were determined
using a modified version of GAGfinder (see Chapter 2) that requires an isotopic
distribution to have peaks A and A+1 to have an intensity above the noise threshold,
with error tolerance between 3 and 5 ppm and considered sulfate losses determined
by the floor of two times the FPI.
3.2.3 Parameter Optimization
In order to determine optimal values for the above parameters, we employed the
simulated annealing (SA) probabilistic optimization procedure. SA is named after
the process of annealing in metallurgy whereby material is heated to the point where
its geometric structure breaks down and it can be shaped, followed by a slow cooling
to re-establish the geometric structure. SA works by randomly moving from one
solution to a neighboring solution until a very good, though not necessarily perfect,
solution is found. During the course of the SA algorithm, if the new solution has
a better fitness than the current solution, the new solution will always be selected;
however, if the new solution has a worse fitness than the current solution, the new
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Figure 3·3: Structures analyzed in this study. A. The ten train-
ing saccharides. B. The three validation saccharides. C. The two iso-
meric mixtures. D. Key for the symbols in the figure. Each analyzed
structure was dissociated via NETD, except testing compounds #6 and
#7, which were dissociated via EDD. The precursor charge states for
these compounds range from -2 to -6. The compounds were selected to
represent diversity in chain length, modification amounts and patterns,
and charge state for GAG oligosaccharides.
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solution may be selected based on a probabilistic criterion. Equation 3.5 shows the
formula for calculating the probability of moving to a worse solution:
P (move) = e
fnew−fcurrent
T (3.5)
Here, fnew and fcurrent represent the fitness scores for the new solution and the current
solution, respectively. T represents a “temperature” parameter that is analogous to
the cooling process in annealing, described above, and “cools” from a value of 1 to 0.
For cases where the new solution’s fitness is worse than the current solution’s, when
T is close to 1, the algorithm will probably still move to that solution, while when
T is close to 0, the algorithm will probably stay at the current solution. Therefore,
at the beginning of the algorithm, it is more likely to move to a worse solution than
toward the end. This helps combat the problem of local maxima.
In our implementation, we employed SA to find a very good solution for GAGrank
on our ten training oligosaccharides. We optimized the five aforementioned parame-
ters as well as the number of fragments returned by GAGfinder. To identify a new
solution we randomly selected one of the six parameters and randomly changed its
value. For α and β, the value could be any number between 0 and 1. For r1 , r2 , and
r3 , the value could be any number between 0 and 10. For the number of fragments
used, the value could be any integer between 5 and 100, or all of the found fragments.
We rounded the value for α and β to the hundredth decimal point and we rounded the
value for r1 , r2 , and r3 to the tenth decimal point. We reduced T by multiplying it
by 0.9. In order to slow the SA process and more completely explore the search space,
we remained at each value of T for 100 iterations. We calculated the fitness of each
solution as the average percent of incorrect sequences with a worse BiRank score than
the correct sequence. For example, if a composition has ten possible sequences, the
solution’s fitness is equal to 1.0 (9/9) if the correct sequence has the highest BiRank
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score, 0.0 (0/9) if the correct sequence has the lowest BiRank score, and 0.778 (7/9)
if the correct sequence has the third-highest BiRank score.
3.3 Results
3.3.1 Optimal Parameters
Parameter optimization via simulated annealing found multiple combinations of pa-
rameters that resulted in optimal performance on the training data, which are sum-
marized in Table 3.1. These combinations all returned a fitness value across the ten
training compounds of 0.9997, meaning that, on average, GAGrank returned a better
ranking score for the correct sequence than 99.97% percent of incorrect sequences.
Each parameter combination follows similar patterns: large values for r1 and r2 ,
small values for r3 , large values for α and β, and between 61 and 97 GAGfinder
fragments used. The large values for r1 can be interpreted as evidence that internal
double glycosidic bond fragments are far less important for GAG sequencing than
terminal fragments. The large values for r2 can be interpreted as evidence that the
fragments’ goodness-of-fit G scores from GAGfinder are more important factors in
GAG sequencing than their intensities. The small values for r3 can be interpreted as
evidence that rare modifications do not need to be punished severely for sequences
without rare modifications to perform well. The large values for α and β can be in-
terpreted as evidence that the initial ranking scores for the fragments and sequences
are much less important to the optimal performance than the placement and widths
of the edges in the graph structure. Finally, the range for the number of fragments
to input into GAGrank mostly relates to the number of fragments initially found
by GAGfinder; for some saccharides, GAGfinder found fewer than 60 fragments in
the spectrum, while for others, GAGfinder found well over 100. The range of 60-70
suffices to get positional detail for modifications without introducing false positives.
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Table 3.1: Summary statistics for each GAGrank parameter
that resulted in the best performance on the testing com-
pounds.
r1 r2 r3 α β # fragments
Minimum 0.5 0.9 0.1 0.77 0.76 61
Maximum 9.8 9.6 1.7 0.99 1.00 97
Mean 5.5 5.2 0.6 0.93 0.92 70
Median 5.4 5.1 0.4 0.98 0.94 68
Mode 9.3 4.9 0.1 0.98 0.94 64
Table 3.2 shows the overall ranking and percent of incorrect sequences outscored
for each of the training compounds in GAGrank and Tables C.2-C.11 show the top
ten (or fewer) GAGrank outputs for each. For eight of the ten training compounds,
GAGrank returned the correct sequence with the best ranking score out of all of the
possible sequences. In test compound #6, GAGrank returned the correct sequence
tied with two other sequences for the second-best ranking score out of all of the
possible sequences. This is likely due to the effect that test compound #6’s rare 3-O-
sulfation without 6-O-sulfation has on the prior sequence rankings; indeed, Table C.7
shows the top four sequences all differ only by the presence (or absence) and location
of the 3-O-sulfation in the sequence. In test compound #9, GAGrank returned the
correct sequence tied with 25 other sequences for the best-ranking score out of all of
the possible sequences, as seen in Table C.10. This is likely due to the large number of
possible sequences for that particular composition, combined with the relative dearth
of fragments found by GAGfinder.
3.3.2 Parameter Validation
Table 3.3 shows the ranking score, overall ranking, and percentile of each of the vali-
dation compounds in GAGrank and Tables C.12-C.14 show the GAGrank outputs for
each. Similar to the results for the test compounds, GAGrank returned the correct se-
quence with the best ranking score out of all of the possible sequences, while GAGrank
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Table 3.2: GAGrank performance for the test compounds us-
ing any of the optimal parameter combinations.
Test
Compound
Ranking
% incorrect
outscored
#1 #1 out of 2 100%
#2 #1 out of 1,848 100%
#3 #1 out of 440 100%
#4 #1 out of 1,584 100%
#5 #1 out of 60 100%
#6 #2-#4 out of 1,848 99.8%
#7 #1 out of 990 100%
#8 #1 out of 3,640 100%
#9 #1-#26 out of 23,298 99.9%
#10 #1 out of 1,092 100%
returned the correct sequence tied with one other sequences for the third-best ranking
score out of all of the possible sequences for the compound with a single 3-O-sulfation
without a 6-O-sulfation. As can be seen in Table C.14, for validation compound #3,
the two sequences with a better ranking score than the actual sequence did not have
any rare modifications, while the actual sequence and the incorrect sequence with
which it tied both have one residue with 3-O-sulfation without 6-O-sulfation. Unlike
the results for test compound #6, one of the two sequences with a better ranking
score than validation compound #3 did not have the correct modification numbers
at each residue in the sequence; the sequence that had the second-best ranking score
placed a sulfate at the 2-O position of the non-reducing end GlcA rather than at the
6-O position of the neighboring GlcN.
Table 3.3: GAGrank performance for the test compounds us-
ing any of the optimal parameter combinations.
Validation
Compound
Ranking
% incorrect
outscored
#1 #1 out of 140 100%
#2 #1 out of 1,584 100%
#3 #3-#4 out of 990 99.7%
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3.3.3 GAGrank and GAG Mixtures
Figure 3·3C shows the structures of two pairs of saccharide isomers used to show
the ability of GAGrank to analyze mixtures. Table 3.4 shows the rankings for each
compound in each of the two mixtures at each of the ratios and Tables C.15-C.28 show
the GAGrank outputs for each. As in the test compounds and validation compounds,
one of the sequences, mixture compound #1B, has a rare modification, 3-O-sulfation
without 6-O-sulfation. Further, this sequence never has the best ranking score at
any mixture ratio, just as in the similar cases in the test compounds and validation
compounds. The sequences corresponding to the remaining three compounds have
the highest-ranking score when they comprise at least 70% of the isomeric mixture
of which they are a part. Furthermore, each of the compounds used in the mixtures
performs as well as it does when it is pure as long as it is 70% or more of the isomeric
mixture.
3.3.4 Runtime Analysis
Information about the runtime of GAGrank on each of the compounds and mixtures
is available in Supplemental Table C.1. With the exception of validation compound
#9, whose composition has 23,298 different possible sequences, GAGrank ran to
completion in under 17 seconds for each compound, with many running to completion
in under 10 seconds. There is a strong relationship between the number of possible
sequences for a compound’s composition and the runtime. GAGrank was tested
on a 2011 MacBook Pro that has a 2.4 GHz Intel Core i5 processor with 4 GB
RAM. GAGrank should run even faster on a more modern machine with greater
computational resources.
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Table 3.4: GAGrank performance for the mixture compounds
using any of the optimal parameter combinations.
Mixture
and ratio
Compound
A rank
Compound A
% incorrect
outscored
Compound
B rank
Compound B
% incorrect
outscored
Mixture #1 100:0
#1 out of
1,584
100% – –
Mixture #1 90:10
#1 out of
1,584
100%
#10-#11 out of
1,584
99.4%
Mixture #1 70:30
#1 out of
1,584
100%
#8-#9 out of
1,584
99.6%
Mixture #1 50:50
#22 out of
1,584
98.7%
#2-#3 out of
1,584
99.9%
Mixture #1 30:70
#64 out of
1,584
96.0%
#2-#4 out of
1,584
99.8%
Mixture #1 10:90
#109 out of
1,584
93.2%
#2-#4 out of
1,584
99.8%
Mixture #1 0:100 – –
#2-#4 out of
1,584
99.8%
Mixture #2 100:0 #1 out of 30 100% – –
Mixture #2 90:10 #1 out of 30 100% #6 out of 30 85.7%
Mixture #2 70:30 #1 out of 30 100% #5 out of 30 89.3%
Mixture #2 50:50 #2 out of 30 100% #1 out of 30 100%
Mixture #2 30:70 #3 out of 30 96.4% #1 out of 30 100%
Mixture #2 10:90 #4 out of 30 92.9% #1 out of 30 100%
Mixture #2 0:100 – – #1 out of 30 100%
3.4 Discussion
Here, we have presented our work on bipartite network representations and analy-
ses for the relationship between GAG sequences and MS2 fragment ions, GAGrank.
GAGrank is an algorithm that ranks nodes using the bipartite network’s structure
and prior information about the sequences and fragments, giving each node an im-
portance score. GAGrank is currently available in command line form. We plan to
merge it and our previous work, GAGfinder (see Chapter 2), into a GAG sequenc-
ing pipeline with a graphical user interface in the near future. The command line
interface is easy to use, with only a few arguments required for operation.
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To our knowledge, this is the first time this approach has been used for the prob-
lem of GAG sequencing, and it has certain inherent advantages. One such advantage
is that the concept of a relationship between sequences and fragments is intuitive and
easy to visualize. Another advantage is that bipartite networks have been exhaus-
tively studied in other fields, meaning that methods for analyzing them have already
been developed. GAGrank, at its most basic level, is simply an implementation of
one of these methods, BiRank [123]. Furthermore, enumerating every sequence that
is possible for a given GAG composition allows for ranking sequences by their impor-
tance in the network, which is analogous to their likelihood.
We used three separate sets of GAG compounds for training and validation. We
optimized GAGrank’s parameters using the ten compounds in our training set, and
found numerous sets of parameters that returned a near-optimal solution. Using
these parameters, we tested GAGrank’s performance on the three compounds in our
validation set, and GAGrank returned a similarly near-optimal solution for these
compounds. We also tested GAGrank’s ability to sequence GAG mixtures on two
separate isomeric mixtures that differed only in one positional sulfation. On these
mixtures, GAGrank performed well, ranking the sequence that made up more of the
mixture highly while ranking the sequence that made up less of the mixture lower.
An intuitive way to view GAGrank’s performance on mixtures is that, the higher
percentage of the mixture a particular sequence is, the higher that sequence ranks.
While GAGrank’s performance on mixtures shows that this method has potential for
characterizing mixture constituents, there is currently no means by which users can
determine that their sample is a mixture.
For the cases in the test set, validation set, and mixture set where the actual
sequence did not rank highest of all the possible sequences, each compound had
a rare modification (3-O-sulfation without 6-O-sulfation on a glucosamine residue)
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that was penalized in the sequences’ query vector. A simple solution to this problem
would be to not punish sequences with rare modifications, but we hypothesize that
this would penalize the final performance of sequences that are much more common
in nature. In the course of parameter optimization, an α equal to 1.00 was tested
numerous times, but never returned the best solution. This case (α=1.00) means
that the sequence ranking is derived entirely from the graph structure, without any
input from the query vectors. Without a near-full complement of fragments in the
spectrum, there will be many sequences that have the exact same edges, and without
prior information, GAGrank cannot distinguish them. We believe that the benefit of
teasing out the exact correct sequence when it has no rare modifications outweighs
the slightly worse performance for those sequences that do have a rare modification.
There are a couple of downsides for GAGrank, both of which are mostly about
user preference. The first is that it requires a peak list from GAGfinder that contain
correctly fit elemental compositions, and will not work on peak lists exported from
the vendor MS2 software generated using averagine approximations. While this adds
an extra step into the pipeline that other programs may not have, it uses the most
appropriate means of assigning monoisotopic peaks and elemental compositions. We
have demonstrated the efficacy and speed of GAGfinder in that project’s manuscript
(see Chapter 2). Another downside is that GAGrank was not developed to work on
metal cationized compounds. Wolff and colleagues were the first group to show how
metal cationization reduces sulfate loss for EDD-dissociated HS compounds [103], and
this approach succeeds in this endeavor. However, including saccharide ions that have
been cationized can severely increase the search space, making the sequencing problem
intractable. Furthermore, none of the samples in this manuscript were cationized, and
GAGrank performed well even with the higher amounts of sulfate loss.
Of course, GAGrank was tested on pure synthetic saccharides, but biological data
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is typically noisy and not pure. A typical experiment that generates biological GAG
data uses liquid chromatography-tandem mass spectrometry (LC-MS2). In LC-MS2,
samples can be separated in the LC column by a number of different means, including
charge or size, and an online mass spectrometer generates MS2 spectra as samples
elute off of the column. This results in a large number of spectra that contain mixtures
of GAG structures. We demonstrated GAGrank’s performance on mixtures of pure
chemicals, and showed that there is potential there, but GAGrank is not yet ready
to handle such large amounts of high throughput data, and it does not perform as
well on mixtures as it does on pure samples. We will continue to develop GAGrank
to handle these situations.
In conclusion, GAGrank demonstrates excellent performance in the difficult task
of GAG sequencing. It ranks sequences accurately based on the complement of frag-
ments found via GAGfinder, and will be a valuable resource for GAG researchers who
need fine structure detail for their samples.
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Chapter 4
Discussion and Future Work
4.1 Summary of Dissertation
The original work described in this dissertation falls into the realm of GAG sequenc-
ing and is intended to be two parts of a modular GAG sequencing pipeline. Any
GAG sequencing project will include four steps: sample preparation/extraction, LC-
MS2, peak determination and annotation, and sequence identification. GAGfinder
and GAGrank are valuable software tools for helping speed up the final two steps in
the pipeline. However, due to the large number of spectra associated with an LC-MS2
experiment, parallelization techniques will need to be employed to ensure an accept-
able runtime. The use of a high-performance computing cluster would be necessary
to attain this goal.
Chapter 1 is an overview and review of automated sequencing methods for all
classes of glycans. It offers background biological information on glycans, a brief
overview of MS2 techniques, a review of existing sequencing methods for branched
glycans and GAGs, and a critical view on GAG sequencing. The methods described
in Chapters 1.3 and 1.4 were inspired by previous work in proteomics and will inspire
future techniques in the pursuit of a gold standard sequencing approach for glycans.
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Chapter 2 describes GAGfinder, the first GAG-specific peak finding software. Tra-
ditional peak finding methods that were designed for proteins and rely on averagine
are improper for GAGs due to their non-uniform distribution of sulfation and the rel-
atively intense isotopic A+2 peak of 34S. The brute force method considers all possible
fragments for a GAG composition and compares the theoretical isotopic distribution
to the spectral data. I showed GAGfinder’s performance on a set of ten synthetic
saccharides and it performs mostly in line with vendor peak finding software, with
the added bonus of automated annotation. Despite being a brute force method writ-
ten in Python, GAGfinder has an acceptable runtime, allowing for rapid analysis of
GAG spectra. In order to handle the large number of spectra associated with high
throughput online LC-MS2, parallelization methods will need to be developed to han-
dle the large number of spectra and a more powerful programming language (e.g. C
or C++) will need to be employed.
Chapter 3 describes GAGrank, a GAG sequencing method that ranks GAG struc-
tures in order of likelihood based on the output of GAGfinder. GAGrank configures
the possible structures and found fragments into a bipartite graph, and uses a node
ranking approach based on a bipartite extension, BiRank [123], of Google’s PageRank
algorithm [122] for ranking search results. I used simulated annealing to optimize the
BiRank parameters using ten synthetic training saccharides, and confirmed the per-
formance using three synthetic validation saccharides. I also showed how GAGrank
performs on two isomeric mixtures of GAG samples, since many GAG sequencing
projects are LC-MS2 analyses of biological samples, which sort along the LC column
by their interactions with the mobile and stationary phases.
The remainder of this chapter contains a general discussion of each software’s role
in the GAG sequencing pipeline, a description of another method for GAG sequenc-
ing that met with poor results, and future directions for these projects. There are
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three appendices after this chapter. Appendix A.1 contains a short description of a
web application for proteomics statistical analysis. Appendix A.2 and appendix A.3
contain supplemental material for Chapters 2 and 3, respectively.
4.2 General Discussion
The first algorithm for biomolecule sequencing was BLAST [129], developed in 1990,
and could be considered a precursor to the expansion of bioinformatics in the hu-
man genome project; truly, sequencing has been a major interest in bioinformatics
since its beginning. Sequencing methods for biomolecules such as DNA and RNA are
established and have the advantage of sample amplification using polymerase chain
reaction (PCR). Sequencing methods for proteins are equally established, and have
the advantage of the use of a reference genome. Sequencing methods for GAGs do
not have these advantages, and therefore require a more nuanced approach. Fur-
thermore, GAG sequencing is tricky, due to their non-uniform distribution of sulfate
modifications, the epimerization of C5 on uronic acid residues, and facile sulfate losses
during MS2. This dissertation has described work I have performed in the pursuit of
a standardized and effective GAG sequencing pipeline.
GAGfinder was developed for more accurate isotopic cluster finding for GAG MS2
spectra and peak annotation. The conventional method by which MS2 spectra clusters
are retrieved is the THRASH algorithm [90]. This method works by fitting potential
isotopic clusters to the average molecular building block, or averagine, for the class of
molecule being tested. This approach works well for protein MS2 analysis, since the
isotopes in peptide fragments typically behave similarly. Where this method runs into
trouble is cases where the averagine does a poor job of modeling the isotopic pattern
of the fragment. These would be cases where the elemental composition changes
dramatically along the molecule, as is the case for GAGs. The same structure could
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have every possible modification location occupied on one end and unoccupied on the
other end, which would lead to entirely different isotopic distributions for fragments
on each end, as demonstrated in Figure 2·1.
The advantage that averagine-reliant cluster finding methods have is speed, com-
pared to enumerating each possible combination of subunits. Methods such as Bruker
Daltonics’ SNAP algorithm only make a single pass through the spectrum, comparing
any potential isotopic clusters to averagine as they are found. GAGfinder utilizes a
brute force method that enumerates and tests all possible fragments at all possible
charge states. This approach works for GAGs due to the relatively limited number
of possible structures for a given chemical composition, as shown in Figure 2·2, and
the runtime numbers shown in Table 2.3 show that speed is not an issue.
Figure 4·1 shows the distributions of hits and misses for all fragments tested by
GAGfinder for sequence #6. The distribution for the hits is to the left of that for
the misses, meaning that their G scores are lower overall than the misses’. This
shows that GAGfinder discriminates between hits and misses properly, and mimics
the behavior of the performance test described in Chapter 2.2.3. A random sampling
of hits and misses would not have two separate G score distributions, as is seen in
the figure.
GAGrank was developed as a technique for ranking GAG sequences by likelihood
based on the isotopic clusters observed in a MS2 spectrum. There are numerous ex-
isting methods for this task, each with its own advantages and drawbacks. GAGrank
takes into consideration the reality that sulfate loss happens during the course of GAG
MS2, does not require any additional chemical workup, and is deterministic. Its bi-
partite network structure represents a natural depiction of the relationship between
possible structures and found fragments, and allows for established network-based
ranking algorithms to be employed.
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Figure 4·1: Distribution of G scores from sequence #6 classi-
fied as hits and misses. The histogram for each class of GAGfinder
result shows that G scores are overall lower for hits than they are for
misses.
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One goal that we had for GAGrank was to be able to assign statistical significance
to each possible structure, allowing for a significance cutoff to filter out unlikely
structures. GAGrank does not currently deliver this kind of numerical significance
value, but there are ways it could be done. For one, we could shuffle the edges of the
network, keeping the same distribution of node degree and edge weight, and then re-
analyze the shuffled networks. The scores for each structure in each shuffled network
themselves would form a distribution against which the score for each structure in
the real network could be compared. Assuming the distribution of shuffled network
scores follows a typical statistical distribution (such as a normal distribution), we can
estimate the probability that the real structure’s score is from that distribution, or
its p-value. A caveat to any GAG sequencing method that enumerates every possible
structure and compares its possible fragments to those found in a MS2 spectrum
is that there is substantial overlap between closely related structures. This means
there would likely be several structures whose p-values would surpass the a priori
significance threshold. In these cases, the overall ranking would represent the best
quantity for distinguishing structures.
Generalizing these methods to handle peptide or branched glycan MS2 data would
be difficult. As previously mentioned, the number of possible peptides grows expo-
nentially with sequence length, making a brute force method for peak finding like
GAGfinder untenable. For branched glycans, the nonstandard branching patterns
that occur would increase search space for fragments, slowing down the process
and making it more convoluted. Given a list of found fragments for peptides or
branched glycans, it would be interesting to see how a GAGrank-like method would
perform. However, methods for sequencing these biomolecular classes are already
well-established, so there is no need for new techniques.
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4.3 GAG Sequencing Using Enrichment Analysis
In my journey toward developing GAGrank, I first experimented with using a gene set
enrichment analysis (GSEA)-like approach. GSEA [130] is a systems biology method
whereby sets of genes are tested for differential expression, rather than individual
genes. In biology, nothing happens in a vacuum. Indeed, the machinery involved in
living systems is considerably interrelated, and often, sets of genes change in tandem
to cause or in response to changes in phenotype. With the advent of high-throughput
nucleic acid sequencing methods, it is now possible to test for changes in expression
across an entire genome at once. GSEA tests for differential expression in gene sets
by ranking the genes in order of a particular test statistic (such as a t-value) and
assessing whether the set is clustered at the top or bottom of the list. Here, a set
could mean any group of genes that works in tandem, from a known genetic pathway
to a group of genes associated with a particular gene ontology (GO) term.
GSEA uses a random walk along the ranked list of genes to determine whether
the genes in a set are distributed randomly along the list, or if they cluster at the top
or bottom. As the walk progresses, a running score – the enrichment score (ES) – is
tabulated, and it increases when it reaches a gene in the current set, and it decreases
when it reaches a gene not in the current set. GSEA calculates the ES starting at both
the top and bottom of the ranked list, so as to check for enrichment in upregulated
and downregulated gene sets. The final ES is the maximum deviation from zero in
the random walk, and it approximates a weighted Kolmogorov-Smirnov statistic. In
order to assess significance of the ES, GSEA permutes the gene names a number of
times and produces a distribution of possible ESs against which the real ES can be
calculated. Finally, multiple testing correction procedures are performed to decrease
the chance of false positive matches.
There are obvious analogs to the parts of GSEA in GAG MS2 analysis. The
68
genes ranked by test statistic are analogous to the output of GAGfinder, sorted by G
score from lowest to highest (recall: a lower G score represents a better fit between
theoretical isotopic distribution and experimental isotopic distribution). The gene
sets are analogous to the possible fragments for a particular sequence. The genome is
analogous to the fragments found in the spectrum. With this in mind, I encoded the
GSEA algorithm for GAG MS2 data for GAG structural determination and tested its
efficacy on a set of ten synthetic GAG saccharides.
Table 4.1 shows the results of the GSEA-like approach on the saccharides shown
in Figure 3·3A. The main takeaway is the approach’s uneven performance on these
standards. We would expect a similar performance for the GSEA-like approach as
that of GAGrank, but the rankings appear to be random. Therefore, we can conclude
that for GAGs, testing for enrichment performs no better than randomly selecting a
structure for a given composition.
Table 4.1: GSEA-inspired method performance for the
GAGrank training compounds. See Figure 3·3A
Test
Compound
Ranking
% incorrect
outscored
#1 #2 out of 2 0%
#2 #1,071-#1,097 out of 1,848 40.7%
#3 #88-#114 out of 440 74.3%
#4 #1,361-#1,372 out of 1,584 13.4%
#5 #3 out of 60 96.6%
#6 #80-#106 out of 1,848 94.3%
#7 #38-#46 out of 990 95.4%
#8 #870-#872 out of 3,640 76.1%
#9 #8,091-#8,258 out of 23,298 64.6%
#10 #142-#144 out of 1,092 86.9%
There are a couple of main culprits for why this approach fails for GAG sequenc-
ing. One problem is the substantial overlap between fragment sets for closely related
sequences. This prevents the approach from being able to significantly separate struc-
tures along the ES axis. Another problem is the nonstandard size of fragment sets
for sequences. Consider sequence #8 in Figure 3·3A. The disaccharide composition
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with one GlcA and one GlcNS occurs seven times in the structure. The set of possible
fragments for this structure does not include that composition seven times, so as to
avoid redundancy, so this reduces the structure’s fragment set size. Since fragment
set size is a parameter in the algorithm and having a smaller set size improves the
ES, we can say that the method is biased toward structures with a lot of redundancy.
Indeed, that structure had one of the better performances during testing, which can
be attributed to its smaller complement of possible fragments.
4.4 Future Work
There are four obvious next steps for these projects. The first is integrating GAG-
finder and GAGrank into a software pipeline and graphical user interface that reduces
user involvement and therefore user error. The second is utilizing machine learning
to assist in uronic acid C5 epimer determination. The third is statistical analysis
of the GAGrank results using the earlier-described permutation test. The fourth is
developing a pipeline for processing LC-MS2 data.
As they currently exist, GAGfinder and GAGrank are exclusively command line
interfaces with many required and optional arguments. This presents a learning
curve for researchers who are not familiar with or comfortable in a command line
setting. A natural way to fix this problem is to integrate the software into a complete
pipeline that has an associated graphical user interface. This allows researchers to
operate in a more conventional window setting. Furthermore, the researcher would
only need to complete one step, as the output from GAGfinder would be streamlined
into GAGrank. This would reduce user error. Since both programs are written in
Python, the use of modules such as flask would make this possible, and in web format.
The problem of uronic acid C5 epimer determination in GAG sequencing is fun-
damentally a classification problem, and can be handled using machine learning clas-
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sification methods. For instance, for a HS octasaccharide, there are four uronic acid
residues, each of which is either GlcA or IdoA. Based on the spectral data, it may be
possible to classify each of these as GlcA or IdoA. One such classification method is
a decision tree, where the answers to a series of questions lead the classification pro-
cedure through a branched tree structure. Furthermore, the random forest procedure
generates a number of decision trees at runtime and selects the one that performs
the best. This is to combat decision trees’ tendency to overfit data. A decision tree
for uronic acid determination would most likely test for the presence or absence of
particular fragments to make a prediction of each uronic acid. While these two meth-
ods are examples of classification procedures that could be used for this problem, any
number of them could also be effective.
While GAGrank demonstrates excellent performance on GAG synthetic saccha-
rides, it does not provide statistical significance in the form of p-values. As described
earlier, one way to achieve this would be a permutation test of the edges in the bipar-
tite network. This would entail keeping all the existing edges and their edge weights
but changing the node at one or both ends of the edge. In order to avoid accidentally
biasing the test, we would need to keep the degree distribution constant for each
node. After each permutation, the BiRank algorithm would be re-run, and the scores
for each sequence would be tabulated into a distribution of scores against which the
score for the real network could be tested. This would allow for the assignment of a
p-value for each possible sequence.
Finally, GAGfinder and GAGrank have shown success in their stated goals in a
proof-of-principle fashion, using only tandem mass spectra of pure, synthetic GAG
standards. When dealing with actual biological data, the data will come from an
LC-MS2 experiment, which results in thousands or millions of mass spectra. This
represents a substantial increase in computational complexity over the single spectrum
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analyses shown in Chapters 2 and 3. In order to be able to handle the excess data from
an LC-MS2 experiment, more nuanced and clever approaches need to be developed.
For one, parallelization using a computing cluster will reduce the amount of time spent
analyzing spectra, since several could be analyzed at a time. Furthermore, Python –
in which GAGfinder and GAGrank are developed – uses dynamic bindings, while its
faster contemporaries such as C++ or Java use static bindings, meaning that each
Python function call requires a string lookup. This adds significant computing time
to the software, and a translation from Python language to a static binding language
would speed up the process.
4.5 Conclusion
In conclusion, the methods described in this dissertation expand the knowledgebase
of GAG sequencing and provide researchers two valuable tools to achieve this end.
It is my hope that these methods will allow researchers to study GAG sequence
more in depth and be able to tease out exactly how GAG sequence affects biological
processes. For instance, since GAG sequence is so strongly associated with cell-cell
interactions, which are key for cancer proliferation, the fine structure could potentially
be a biomarker for different types of cancer.
Appendix A
PEAKSviz: Data visualization and
statistical analysis of PEAKS
proteomics data
A.1 Introduction
As its name implies, label-free quantification (LFQ) is a proteomics method for quan-
tifying proteins in a set of biological samples without the use of an isotopic labeling
tag. In a liquid chromatography/tandem mass spectrometry (LC-MS2) experiment,
the MS2 stage is for peptide identification, while the MS1 stage is for peptide quan-
tification. LFQ extracts precursor ion signal at the MS1 level for abundant peptides.
These peptides, and their associated abundances, can then be mapped back to protein
sequences using sequence alignment techniques.
PEAKS (Bioinformatics Solutions, Waterloo, ON, Canada) is a software suite that
assists researchers in performing all of these tasks. In a PEAKS proteomics experi-
ment, researchers upload tandem mass spectrometry data for their samples, and they
can download a comma-separated variable (CSV) file containing this information.
There are a number of input parameters, such as identification false discovery rate
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(FDR) and the number of unique identified peptides required for protein identifica-
tion, among others. These parameters are determined a priori by the researchers,
and depend on their preferences for how narrow they want the search to be.
We developed a web application, PEAKSviz, in R Shiny for data visualization and
statistical analysis of PEAKS proteomics output data. PEAKSviz is freely available to
use and its source code is publicly available. PEAKSviz produces heatmaps, principal
component analysis (PCA) plots, hierarchical clustering dendrograms, and differential
analysis at either the protein or the peptide level.
A.2 PEAKSviz overview
There are two possible analysis types for PEAKSviz: protein-level and peptide-level.
Each of these analysis types produces the same data visualizations and statistical
analyses on different PEAKS outputs. The protein-level analysis uses the PEAKS
output file proteins.csv as input, while the peptide-level analysis uses the PEAKS
output file protein-peptides.csv as input. The steps of the pipeline are described be-
low, and screenshots from PEAKSviz are shown in Figure A·1. Data used to generate
the visualizations in Figure A·1B-D are described in [131], and can be downloaded
for testing purposes via the PRIDE [101] public repository with data set identifier
PXD008990.
Step 1: Load data – In this step, the user uploads the appropriate PEAKS output
file as input into the pipeline and inputs several other pieces of information about
the project: the project name, imputation method, number of different groups in the
data, and a protein or peptide list for subsetting the data. Due to the significant
missing data problem in LFQ experiments, PEAKSviz imputes the missing values
by one of two methods: median imputation, where each missing value is converted
to the median intensity for the corresponding sample, or k-nearest neighbors (KNN)
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Figure A·1: Screenshots from the PEAKSviz user interface.
A. Data input page, including inputs for the PEAKS CSV file, project
name, imputation method, group number, and proteins for which to
filter data. B. Heatmap on logged, scaled protein expression data. C.
PCA plot for logged, scaled protein expression data. D. Hierarchical
clustering dendrogram for logged, scaled protein expression data.
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imputation, where each missing value is converted to the average intensity for that
protein across the k most similar samples. The number of different groups corresponds
to the number of different types of sample in the project (e.g. two groups, if comparing
disease to healthy). Finally, the data can be subsetted to a protein or list of proteins.
These could be proteins associated with a gene ontology (GO) term, or a biochemical
process. For the peptides analysis, only one protein may be selected to subset the
data.
Step 2: Select columns – In this step, the user tells PEAKSviz what columns
in the file correspond to the intensity data for the proteins or peptides. PEAKSviz
attempts to guess at which columns the user wants by searching the column names
for columns containing the word “area.” This is due to the tendency of test users to
label the samples’ intensities as areas, for the area under the peak.
Step 3: Group samples – In this step, the user tells PEAKSviz which samples
belong in which group, if the user designated in step 1 that there are groups in the
data. This is for appropriate color-coding for the PCA diagram in step 4.
Step 4: Results – Here, the results of the analyses are produced. There are four
or five outputs, depending on if the user designated in step 1 that there are groups in
the data or not. These outputs are the scaled and imputed intensity data, a heatmap,
a PCA plot and contributions to principal component (PC) variation, a hierarchical
clustering dendrogram, and differential expression.
A.3 Implementation
PEAKSviz was developed in the R statistical language [132] and the corresponding
user interface was developed using the R package Shiny [133]. The KNN imputa-
tion procedure utilizes the impute.knn function of the Bioconductor package impute
[134]. The heatmaps are rendered using the heatmap.2 function of the R package
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gplots [135]. The PCA plots are rendered using various functions from the R package
ggfortify [136, 137]. Every other step in the algorithm is performed using a base R
function.
A.4 Conclusion
Here we have presented PEAKSviz, a web application for data visualization and
statistical analysis of protein expression data. PEAKSviz works on any modern web
browser, and requires only basic user interaction. PEAKSviz is perfect for researchers
who wish to harness R’s statistical data visualization techniques without needing to
learn the language. We hope that other groups use PEAKSviz for their proteomics
statistical analysis needs.
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Figure B·1: Relational schema for GAGfragDB.
Figure B·2: Cross-ring cleavage patterns considered in
GAGfinder.
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Figure B·3: Distributions of each saccharide’s PerfScore per-
mutation test. Arrows point to the PerfScore for each sequence.
(a) Distributions of the permutation scores
for saccharide #1 against the background.
(b) Distributions of the permutation scores
for saccharide #2 against the background.
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(c) Distributions of the permutation scores
for saccharide #3 against the background.
(d) Distributions of the permutation scores
for saccharide #4 against the background.
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(e) Distributions of the permutation scores
for saccharide #5 against the background.
(f) Distributions of the permutation scores
for saccharide #6 against the background.
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(g) Distributions of the permutation scores
for saccharide #7 against the background.
(h) Distributions of the permutation scores
for saccharide #8 against the background.
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(i) Distributions of the permutation scores for
saccharide #9 against the background.
(j) Distributions of the permutation scores for
saccharide #10 against the background.
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Figure B·4: Precision-recall curves for GAGfinder and SNAP
for each saccharide.
(a) Precision-recall curve for GAGfinder and SNAP
for saccharide #1
(b) Precision-recall curve for GAGfinder and SNAP
for saccharide #2
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(c) Precision-recall curve for GAGfinder and SNAP
for saccharide #3
(d) Precision-recall curve for GAGfinder and SNAP
for saccharide #4
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(e) Precision-recall curve for GAGfinder and SNAP
for saccharide #5
(f) Precision-recall curve for GAGfinder and SNAP
for saccharide #6
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(g) Precision-recall curve for GAGfinder and SNAP
for saccharide #7
(h) Precision-recall curve for GAGfinder and SNAP
for saccharide #8
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(i) Precision-recall curve for GAGfinder and SNAP
for saccharide #9
(j) Precision-recall curve for GAGfinder and SNAP
for saccharide #10
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Figure B·5: Annotated spectra for each test saccharide.
(a) Annotated spectrum for saccharide #1
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(b) Annotated spectrum for saccharide #2
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(c) Annotated spectrum for saccharide #3
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(d) Annotated spectrum for saccharide #4
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(e) Annotated spectrum for saccharide #5
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(f) Annotated spectrum for saccharide #6
95
(g) Annotated spectrum for saccharide #7
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(h) Annotated spectrum for saccharide #8
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(i) Annotated spectrum for saccharide #9
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(j) Annotated spectrum for saccharide #10
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Figure B·6: Zoomed in images of the Y1, 1- and Y1-S, 1- ions
mentioned in Chapter 2. Notice how the ions are picked out of
other high-intensity ions.
(a) Y1-S, 1-
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(b) Y1, 1-
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Table C.1: Time data for each of the tested compounds. The
two sections at the bottom represent the two isomeric mixtures tested.
Compound
Precursor
z
Dissociation
Method
Runtime
(s)
#
sequences
#
fragments
Training #1 -2 NETD 4.711 2 19
Training #2 -4 NETD 9.614 1,848 50
Training #3 -3 NETD 4.207 440 29
Training #4 -5 NETD 8.647 1,584 57
Training #5 -4 NETD 3.426 60 37
Training #6 -5 EDD 12.913 1,848 93
Training #7 -4 EDD 8.654 990 54
Training #8 -5 NETD 16.128 3,640 38
Training #9 -6 NETD 171.189 23,298 15
Training #10 -4 NETD 16.127 1,092 48
Validation #1 -4 NETD 6.484 140 12
Validation #2 -5 NETD 8.454 1,584 54
Validation #3 -6 NETD 7.166 990 55
1A:1B, 100:0 8.336 47
1A:1B, 90:10 9.588 51
1A:1B, 70:30 9.484 49
1A:1B, 50:50 -6 NETD 9.629 1,584 45
1A:1B, 30:70 8.964 49
1A:1B, 10:90 10.303 43
1A:1B, 0:100 8.137 42
2A:2B, 100:0 2.444 28
2A:2B, 90:10 1.512 27
2A:2B, 70:30 1.514 28
2A:2B, 50:50 -3 NETD 1.588 30 32
2A:2B, 30:70 1.528 33
2A:2B, 10:90 1.518 28
2A:2B, 0:100 1.677 28
Table C.2: Training compound #1 results. Row with correct
sequence is italicized.
Sequence
GAGrank
score
HexNAc-HexA-HexNAc-HexA 0.303482198
HexA-HexNAc-HexA-HexNAc 0.242934209
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Table C.3: Training compound #2 results. Row with correct
sequence is italicized.
Sequence
GAGrank
score
HexA-HexNS6S-HexA-HexNS6S-HexA-HexNS6S 0.004031581
HexA-HexNS6S-HexA-HexNS6S-HexA-HexNS3S 0.004028602
HexA-HexNS6S-HexA-HexNS3S-HexA-HexNS6S 0.004028602
HexA-HexNS3S-HexA-HexNS6S-HexA-HexNS6S 0.004028602
HexA-HexNS6S-HexA-HexNS3S-HexA-HexNS3S 0.004026018
HexA-HexNS3S-HexA-HexNS6S-HexA-HexNS3S 0.004026018
HexA-HexNS3S-HexA-HexNS3S-HexA-HexNS6S 0.004026018
HexA-HexNS6S-HexA-HexNS6S-HexA-HexN3S6S 0.004024705
HexA-HexNS6S-HexA-HexN3S6S-HexA-HexNS6S 0.004024705
HexA-HexN3S6S-HexA-HexNS6S-HexA-HexNS6S 0.004024705
Table C.4: Training compound #3 results. Row with correct
sequence is italicized.
Sequence
GAGrank
score
HexNS-HexA-HexNS-HexA-HexNS-HexA 0.010001795
HexNS-HexA-HexNS-HexA-HexN6S-HexA 0.009963715
HexNS-HexA-HexN6S-HexA-HexNS-HexA 0.009963715
HexN6S-HexA-HexNS-HexA-HexNS-HexA 0.009963715
HexNS-HexA-HexN6S-HexA-HexN6S-HexA 0.009937320
HexN6S-HexA-HexNS-HexA-HexN6S-HexA 0.009937320
HexN6S-HexA-HexN6S-HexA-HexNS-HexA 0.009937320
HexNS-HexA-HexNS-HexA-HexN3S-HexA 0.009927102
HexNS-HexA-HexN3S-HexA-HexNS-HexA 0.009927102
HexN3S-HexA-HexNS-HexA-HexNS-HexA 0.009927102
Table C.5: Training compound #4 results. Row with correct
sequence is italicized.
Sequence
GAGrank
score
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexNS6S 0.003969474
HexA-HexNS6S-HexA2S-HexNS3S-HexA-HexNS6S 0.003966378
HexA-HexNS3S-HexA2S-HexNS6S-HexA-HexNS6S 0.003966378
HexA-HexNS3S-HexA2S-HexNS3S-HexA-HexNS6S 0.003963694
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexN3S6S 0.003962329
HexA-HexN3S6S-HexA2S-HexNS6S-HexA-HexNS6S 0.003962329
HexA-HexNS6S-HexA2S-HexNS3S-HexA-HexN3S6S 0.003960183
HexA-HexNS3S-HexA2S-HexNS6S-HexA-HexN3S6S 0.003960183
HexA-HexN3S6S-HexA2S-HexNS3S-HexA-HexNS6S 0.003960183
HexA-HexNS3S-HexA2S-HexNS3S-HexA-HexN3S6S 0.003958323
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Table C.6: Training compound #5 results. Row with correct
sequence is italicized.
Sequence
GAGrank
score
HexNS-HexA-HexNAc-HexA-HexNAc-HexA 0.037645074
HexN3S-HexA-HexNAc-HexA-HexNAc-HexA 0.036493308
HexN6S-HexA-HexNAc-HexA-HexNAc-HexA 0.036115857
HexN-HexA2S-HexNAc-HexA-HexNAc-HexA 0.032541920
HexNAc-HexA-HexNS-HexA-HexNAc-HexA 0.029770158
HexNAc-HexA-HexN6S-HexA-HexNAc-HexA 0.029618825
HexNAc-HexA2S-HexN-HexA-HexNAc-HexA 0.029618730
HexN-HexA-HexNAc6S-HexA-HexNAc-HexA 0.029618561
HexN-HexA-HexNAc3S-HexA-HexNAc-HexA 0.029573110
HexNAc-HexA-HexN3S-HexA-HexNAc-HexA 0.029473320
Table C.7: Training compound #6 results. Row with correct
sequence is italicized.
Sequence
GAGrank
score
HexA-HexNS6S-HexA-HexNS6S-HexA-HexNS6S 0.003152165
HexA-HexNS6S-HexA-HexNS6S-HexA-HexNS3S 0.003149186
HexA-HexNS6S-HexA-HexNS3S-HexA-HexNS6S 0.003149186
HexA-HexNS3S-HexA-HexNS6S-HexA-HexNS6S 0.003149186
HexA-HexNS6S-HexA-HexNS3S-HexA-HexNS3S 0.003146602
HexA-HexNS3S-HexA-HexNS6S-HexA-HexNS3S 0.003146602
HexA-HexNS3S-HexA-HexNS3S-HexA-HexNS6S 0.003146602
HexA-HexNS6S-HexA-HexNS6S-HexA-HexN3S6S 0.003145289
HexA-HexNS6S-HexA-HexN3S6S-HexA-HexNS6S 0.003145289
HexA-HexN3S6S-HexA-HexNS6S-HexA-HexNS6S 0.003145289
Table C.8: Training compound #7 results. Row with correct
sequence is italicized.
Sequence
GAGrank
score
HexA-HexNS6S-HexA-HexNS3S6S-HexA2S-HexNS6S 0.003227609
HexA-HexNS6S-HexA-HexNS3S6S-HexA2S-HexNS3S 0.003223225
HexA-HexNS3S-HexA-HexNS3S6S-HexA2S-HexNS6S 0.003223225
HexA-HexNS3S-HexA-HexNS3S6S-HexA2S-HexNS3S 0.003219425
HexA-HexNS6S-HexA-HexNS3S6S-HexA2S-HexN3S6S 0.003217493
HexA-HexN3S6S-HexA-HexNS3S6S-HexA2S-HexNS6S 0.003217493
HexA-HexNS3S-HexA-HexNS3S6S-HexA2S-HexN3S6S 0.003214454
HexA-HexN3S6S-HexA-HexNS3S6S-HexA2S-HexNS3S 0.003214454
HexA-HexN3S6S-HexA-HexNS3S6S-HexA2S-HexN3S6S 0.003210481
HexA-HexNS6S-HexA-HexNS6S-HexA2S-HexNS3S6S 0.003204943
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Table C.9: Training compound #8 results. Row with correct
sequence is italicized.
Sequence
GAGrank
score
HexNS-HexA-HexNS-HexA-HexNS-HexA-HexNS-HexA 0.003375208
HexN6S-HexA-HexNS-HexA-HexNS-HexA-HexNS-HexA 0.003368827
HexN3S-HexA-HexNS-HexA-HexNS-HexA-HexNS-HexA 0.003362692
HexNS-HexA-HexN6S-HexA-HexNS-HexA-HexNS-HexA 0.003323178
HexNS-HexA-HexNS-HexA-HexNS-HexA-HexN6S-HexA 0.003322108
HexN6S-HexA-HexN6S-HexA-HexNS-HexA-HexNS-HexA 0.003318755
HexN6S-HexA-HexNS-HexA-HexNS-HexA-HexN6S-HexA 0.003317685
HexNS-HexA-HexN3S-HexA-HexNS-HexA-HexNS-HexA 0.003317043
HexNS-HexA-HexNS-HexA-HexNS-HexA-HexN3S-HexA 0.003315973
HexN6S-HexA-HexN3S-HexA-HexNS-HexA-HexNS-HexA 0.003314502
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Table C.10: Training compound #9 results. Row with correct
sequence is italicized.
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Table C.11: Training compound #10 results. Row with correct
sequence is italicized.
Sequence
GAGrank
score
HexNS-HexA-HexNS-HexA-HexNAc-HexA-HexNAc-HexA 0.009106014
HexNS-HexA-HexN6S-HexA-HexNAc-HexA-HexNAc-HexA 0.009094131
HexNS-HexA-HexN3S-HexA-HexNAc-HexA-HexNAc-HexA 0.009082706
HexN6S-HexA-HexNS-HexA-HexNAc-HexA-HexNAc-HexA 0.008972119
HexN6S-HexA-HexN6S-HexA-HexNAc-HexA-HexNAc-HexA 0.008963882
HexN6S-HexA-HexN3S-HexA-HexNAc-HexA-HexNAc-HexA 0.008955963
HexN3S-HexA-HexNS-HexA-HexNAc-HexA-HexNAc-HexA 0.008860432
HexN3S-HexA-HexN6S-HexA-HexNAc-HexA-HexNAc-HexA 0.008855701
HexN3S-HexA-HexN3S-HexA-HexNAc-HexA-HexNAc-HexA 0.008851152
HexNS-HexA-HexN-HexA2S-HexNAc-HexA-HexNAc-HexA 0.008812561
Table C.12: Validation compound #1 results. Row with correct
sequence is italicized.
Sequence
GAGrank
score
HexA-HexNS-HexA2S-HexNS6S 0.027313000
HexA2S-HexN-HexA2S-HexNS6S 0.027241385
HexA-HexNS-HexA2S-HexN3S6S 0.027241385
HexA-HexN6S-HexA2S-HexNS6S 0.027241385
HexA2S-HexN-HexA2S-HexN3S6S 0.027191746
HexA-HexN6S-HexA2S-HexN3S6S 0.027191746
HexA-HexN3S-HexA2S-HexNS6S 0.027172529
HexA-HexN3S-HexA2S-HexN3S6S 0.027144018
HexA-HexNS-HexA2S-HexNS3S 0.026174395
HexA2S-HexN-HexA2S-HexNS3S 0.026112302
Table C.13: Validation compound #2 results. Row with correct
sequence is italicized.
Sequence
GAGrank
score
HexA-HexNS6S-HexA-HexNS6S-HexA2S-HexNS6S 0.005042149
HexA-HexNS6S-HexA-HexNS3S-HexA2S-HexNS6S 0.005039053
HexA-HexNS3S-HexA-HexNS6S-HexA2S-HexNS6S 0.005039053
HexA-HexNS3S-HexA-HexNS3S-HexA2S-HexNS6S 0.005036369
HexA-HexN3S6S-HexA-HexNS6S-HexA2S-HexNS6S 0.005035004
HexA-HexN3S6S-HexA-HexNS3S-HexA2S-HexNS6S 0.005032858
HexA-HexNS6S-HexA-HexNS6S-HexA2S-HexNS3S 0.004997753
HexA-HexNS6S-HexA-HexN3S6S-HexA2S-HexNS6S 0.004995329
HexA-HexNS6S-HexA-HexNS3S-HexA2S-HexNS3S 0.004995069
HexA-HexNS3S-HexA-HexNS6S-HexA2S-HexNS3S 0.004995069
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Table C.14: Validation compound #3 results. Row with correct
sequence is italicized.
Sequence
GAGrank
score
HexA-HexNS6S-HexA2S-HexNS6S-HexA2S-HexNS6S 0.004176479
HexA2S-HexNS-HexA2S-HexNS6S-HexA2S-HexNS6S 0.004176474
HexA-HexNS6S-HexA2S-HexNS6S-HexA2S-HexNS3S 0.004172096
HexA-HexNS6S-HexA2S-HexNS3S-HexA2S-HexNS6S 0.004172096
HexA2S-HexNS-HexA2S-HexNS6S-HexA2S-HexNS3S 0.004172090
HexA2S-HexNS-HexA2S-HexNS3S-HexA2S-HexNS6S 0.004172090
HexA-HexNS6S-HexA2S-HexNS3S-HexA2S-HexNS3S 0.004168295
HexA2S-HexNS-HexA2S-HexNS3S-HexA2S-HexNS3S 0.004168290
HexA-HexNS6S-HexA2S-HexNS6S-HexA2S-HexN3S6S 0.004166363
HexA-HexN3S6S-HexA2S-HexNS6S-HexA2S-HexNS6S 0.004166363
Table C.15: Mixture compound #1 100:0 results. Row(s) with
correct sequence(s) is italicized.
Sequence
GAGrank
score
HexA-HexNS6S-HexA-HexNS3S6S-HexA-HexNS6S 0.002950081
HexA-HexNS3S-HexA-HexNS3S6S-HexA-HexNS6S 0.002945489
HexA-HexNS6S-HexA-HexNS3S6S-HexA-HexN3S6S 0.002940470
HexA-HexN3S6S-HexA-HexNS3S6S-HexA-HexNS6S 0.002940470
HexA-HexNS3S-HexA-HexNS3S6S-HexA-HexN3S6S 0.002938263
HexA-HexN3S6S-HexA-HexNS3S6S-HexA-HexN3S6S 0.002935852
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexNS6S 0.002931145
HexA-HexNS6S-HexA2S-HexNS3S-HexA-HexNS6S 0.002926553
HexA-HexNS3S-HexA2S-HexNS6S-HexA-HexNS6S 0.002926553
HexA-HexNS3S-HexA2S-HexNS3S-HexA-HexNS6S 0.002923101
Table C.16: Mixture compound #1 90:10 results. Row(s) with
correct sequence(s) is italicized.
Sequence
GAGrank
score
HexA-HexNS6S-HexA-HexNS3S6S-HexA-HexNS6S 0.002753264
HexA-HexNS3S-HexA-HexNS3S6S-HexA-HexNS6S 0.002748671
HexA-HexNS6S-HexA-HexNS3S6S-HexA-HexN3S6S 0.002743652
HexA-HexN3S6S-HexA-HexNS3S6S-HexA-HexNS6S 0.002743652
HexA-HexNS3S-HexA-HexNS3S6S-HexA-HexN3S6S 0.002741446
HexA-HexN3S6S-HexA-HexNS3S6S-HexA-HexN3S6S 0.002739035
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexNS6S 0.002724934
HexA2S-HexNS-HexA-HexNS3S6S-HexA-HexNS6S 0.002724480
HexA-HexNS6S-HexA-HexNS3S6S-HexA-HexNS3S 0.002720716
HexA-HexNS6S-HexA2S-HexNS3S-HexA-HexNS6S 0.002720341
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Table C.17: Mixture compound #1 70:30 results. Row(s) with
correct sequence(s) is italicized.
Sequence
GAGrank
score
HexA-HexNS6S-HexA-HexNS3S6S-HexA-HexNS6S 0.002234407
HexA-HexNS3S-HexA-HexNS3S6S-HexA-HexNS6S 0.002229814
HexA-HexNS6S-HexA-HexNS3S6S-HexA-HexN3S6S 0.002224795
HexA-HexN3S6S-HexA-HexNS3S6S-HexA-HexNS6S 0.002224795
HexA-HexNS3S-HexA-HexNS3S6S-HexA-HexN3S6S 0.002222589
HexA-HexN3S6S-HexA-HexNS3S6S-HexA-HexN3S6S 0.002220177
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexNS6S 0.002210470
HexA-HexNS6S-HexA2S-HexNS3S-HexA-HexNS6S 0.002205878
HexA-HexNS3S-HexA2S-HexNS6S-HexA-HexNS6S 0.002205878
HexA-HexNS6S-HexA-HexNS3S6S-HexA-HexNS3S 0.002204972
Table C.18: Mixture compound #1 50:50 results. Row(s) with
correct sequence(s) is italicized.
Sequence
GAGrank
score
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexNS6S 0.003179077
HexA-HexNS6S-HexA2S-HexNS3S-HexA-HexNS6S 0.003174485
HexA-HexNS3S-HexA2S-HexNS6S-HexA-HexNS6S 0.003174485
HexA-HexNS3S-HexA2S-HexNS3S-HexA-HexNS6S 0.003171033
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexN3S6S 0.003169466
HexA-HexNS6S-HexA2S-HexN3S6S-HexA-HexNS6S 0.003169466
HexA-HexN3S6S-HexA2S-HexNS6S-HexA-HexNS6S 0.003169466
HexA-HexNS6S-HexA2S-HexNS3S-HexA-HexN3S6S 0.003167259
HexA-HexNS3S-HexA2S-HexNS6S-HexA-HexN3S6S 0.003167259
HexA-HexNS3S-HexA2S-HexN3S6S-HexA-HexNS6S 0.003167259
Table C.19: Mixture compound #1 30:70 results. Row(s) with
correct sequence(s) is italicized.
Sequence
GAGrank
score
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexNS6S 0.002927872
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexNS3S 0.002923280
HexA-HexNS6S-HexA2S-HexNS3S-HexA-HexNS6S 0.002923280
HexA-HexNS3S-HexA2S-HexNS6S-HexA-HexNS6S 0.002923280
HexA-HexNS6S-HexA2S-HexNS3S-HexA-HexNS3S 0.002919827
HexA-HexNS3S-HexA2S-HexNS6S-HexA-HexNS3S 0.002919827
HexA-HexNS3S-HexA2S-HexNS3S-HexA-HexNS6S 0.002919827
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexN3S6S 0.002918261
HexA-HexNS6S-HexA2S-HexN3S6S-HexA-HexNS6S 0.002918261
HexA-HexN3S6S-HexA2S-HexNS6S-HexA-HexNS6S 0.002918261
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Table C.20: Mixture compound #1 10:90 results. Row(s) with
correct sequence(s) is italicized.
Sequence
GAGrank
score
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexNS6S 0.003106300
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexNS3S 0.003101708
HexA-HexNS6S-HexA2S-HexNS3S-HexA-HexNS6S 0.003101708
HexA-HexNS3S-HexA2S-HexNS6S-HexA-HexNS6S 0.003101708
HexA-HexNS6S-HexA2S-HexNS3S-HexA-HexNS3S 0.003098255
HexA-HexNS3S-HexA2S-HexNS6S-HexA-HexNS3S 0.003098255
HexA-HexNS3S-HexA2S-HexNS3S-HexA-HexNS6S 0.003098255
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexN3S6S 0.003096689
HexA-HexNS6S-HexA2S-HexN3S6S-HexA-HexNS6S 0.003096689
HexA-HexN3S6S-HexA2S-HexNS6S-HexA-HexNS6S 0.003096689
Table C.21: Mixture compound #1 0:100 results. Row(s) with
correct sequence(s) is italicized.
Sequence
GAGrank
score
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexNS6S 0.003356457
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexNS3S 0.003351864
HexA-HexNS6S-HexA2S-HexNS3S-HexA-HexNS6S 0.003351864
HexA-HexNS3S-HexA2S-HexNS6S-HexA-HexNS6S 0.003351864
HexA-HexNS6S-HexA2S-HexNS3S-HexA-HexNS3S 0.003348412
HexA-HexNS3S-HexA2S-HexNS6S-HexA-HexNS3S 0.003348412
HexA-HexNS3S-HexA2S-HexNS3S-HexA-HexNS6S 0.003348412
HexA-HexNS6S-HexA2S-HexNS6S-HexA-HexN3S6S 0.003346845
HexA-HexNS6S-HexA2S-HexN3S6S-HexA-HexNS6S 0.003346845
HexA-HexN3S6S-HexA2S-HexNS6S-HexA-HexNS6S 0.003346845
Table C.22: Mixture compound #2 100:0 results. Row(s) with
correct sequence(s) is italicized.
Sequence
GAGrank
score
HexA-HexNAc6S-HexA-HexNAc6S 0.050216157
HexA-HexNAc3S-HexA-HexNAc6S 0.050113371
HexA-HexNAc6S-HexA-HexNAc3S 0.049088079
HexA-HexNAc3S-HexA-HexNAc3S 0.049010809
HexA2S-HexNAc-HexA-HexNAc6S 0.044482264
HexA2S-HexNAc-HexA-HexNAc3S 0.043217273
HexA-HexNAc6S-HexA2S-HexNAc 0.042408065
HexA-HexNAc-HexA2S-HexNAc6S 0.042394732
HexA-HexNAc3S-HexA2S-HexNAc 0.042305279
HexA-HexNAc-HexA2S-HexNAc3S 0.041070433
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Table C.23: Mixture compound #2 90:10 results. Row(s) with
correct sequence(s) is italicized.
Sequence
GAGrank
score
HexA-HexNAc6S-HexA-HexNAc6S 0.050206896
HexA-HexNAc3S-HexA-HexNAc6S 0.050108197
HexA-HexNAc6S-HexA-HexNAc3S 0.049038267
HexA-HexNAc3S-HexA-HexNAc3S 0.048964070
HexA2S-HexNAc-HexA-HexNAc6S 0.044165358
HexA-HexNAc-HexA2S-HexNAc6S 0.043328393
HexA2S-HexNAc-HexA-HexNAc3S 0.042844929
HexA-HexNAc6S-HexA2S-HexNAc 0.042038936
HexA-HexNAc-HexA2S-HexNAc3S 0.041983674
HexA-HexNAc3S-HexA2S-HexNAc 0.041940237
Table C.24: Mixture compound #2 70:30 results. Row(s) with
correct sequence(s) is italicized.
Sequence
GAGrank
score
HexA-HexNAc6S-HexA-HexNAc6S 0.049219907
HexA-HexNAc3S-HexA-HexNAc6S 0.049121208
HexA-HexNAc6S-HexA-HexNAc3S 0.048072594
HexA-HexNAc3S-HexA-HexNAc3S 0.047998397
HexA-HexNAc-HexA2S-HexNAc6S 0.044810770
HexA-HexNAc-HexA2S-HexNAc3S 0.043556734
HexA2S-HexNAc-HexA-HexNAc6S 0.043326820
HexA2S-HexNAc-HexA-HexNAc3S 0.042031565
HexA-HexNAc6S-HexA2S-HexNAc 0.041193679
HexA-HexNAc3S-HexA2S-HexNAc 0.041094980
Table C.25: Mixture compound #2 50:50 results. Row(s) with
correct sequence(s) is italicized.
Sequence
GAGrank
score
HexA-HexNAc-HexA2S-HexNAc6S 0.041595545
HexA-HexNAc6S-HexA-HexNAc6S 0.041053720
HexA-HexNAc3S-HexA-HexNAc6S 0.040958795
HexA-HexNAc-HexA2S-HexNAc3S 0.040662793
HexA-HexNAc6S-HexA-HexNAc3S 0.040106248
HexA-HexNAc3S-HexA-HexNAc3S 0.040034887
HexA-HexNAc-HexA-HexNAc3S6S 0.036556982
HexA2S-HexNAc-HexA-HexNAc6S 0.036452322
HexA2S-HexNAc-HexA-HexNAc3S 0.035393278
HexA-HexNAc6S-HexA2S-HexNAc 0.034580137
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Table C.26: Mixture compound #2 30:70 results. Row(s) with
correct sequence(s) is italicized.
Sequence
GAGrank
score
HexA-HexNAc-HexA2S-HexNAc6S 0.042476891
HexA-HexNAc-HexA2S-HexNAc3S 0.041595135
HexA-HexNAc6S-HexA-HexNAc6S 0.040232800
HexA-HexNAc3S-HexA-HexNAc6S 0.040137875
HexA-HexNAc6S-HexA-HexNAc3S 0.039302779
HexA-HexNAc3S-HexA-HexNAc3S 0.039231418
HexA-HexNAc-HexA-HexNAc3S6S 0.037743468
HexA2S-HexNAc-HexA-HexNAc6S 0.034790011
HexA-HexNAc6S-HexA2S-HexNAc 0.033899028
HexA-HexNAc3S-HexA2S-HexNAc 0.033804104
Table C.27: Mixture compound #2 10:90 results. Row(s) with
correct sequence(s) is italicized.
Sequence
GAGrank
score
HexA-HexNAc-HexA2S-HexNAc6S 0.045719214
HexA-HexNAc-HexA2S-HexNAc3S 0.044614502
HexA-HexNAc-HexA-HexNAc3S6S 0.041820284
HexA-HexNAc6S-HexA-HexNAc6S 0.041002384
HexA-HexNAc3S-HexA-HexNAc6S 0.040907459
HexA-HexNAc6S-HexA-HexNAc3S 0.039772429
HexA-HexNAc3S-HexA-HexNAc3S 0.039701068
HexA2S-HexNAc-HexA-HexNAc6S 0.036061804
HexA-HexNAc6S-HexA2S-HexNAc 0.034878209
HexA-HexNAc3S-HexA2S-HexNAc 0.034783284
Table C.28: Mixture compound #2 0:100 results. Row(s) with
correct sequence(s) is italicized.
Sequence
GAGrank
score
HexA-HexNAc-HexA2S-HexNAc6S 0.058691828
HexA-HexNAc-HexA2S-HexNAc3S 0.057379903
HexA-HexNAc-HexA-HexNAc3S6S 0.055061707
HexA-HexNAc3S-HexA-HexNAc6S 0.050889993
HexA-HexNAc6S-HexA-HexNAc6S 0.049617336
HexA-HexNAc3S-HexA-HexNAc3S 0.049419760
HexA-HexNAc6S-HexA-HexNAc3S 0.048078461
HexA-HexNAc3S-HexA2S-HexNAc 0.045131311
HexA-HexNAc6S-HexA2S-HexNAc 0.043674420
HexA-HexNAc3S6S-HexA-HexNAc 0.043674420
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